<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">38744</article-id><article-id pub-id-type="doi">10.7554/eLife.38744</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Metformin reverses early cortical network dysfunction and behavior changes in Huntington’s disease</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-114881"><name><surname>Arnoux</surname><given-names>Isabelle</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4530-9944</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-114882"><name><surname>Willam</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-114883"><name><surname>Griesche</surname><given-names>Nadine</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114884"><name><surname>Krummeich</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114885"><name><surname>Watari</surname><given-names>Hirofumi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114886"><name><surname>Offermann</surname><given-names>Nina</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114887"><name><surname>Weber</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114888"><name><surname>Narayan Dey</surname><given-names>Partha</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114889"><name><surname>Chen</surname><given-names>Changwei</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114890"><name><surname>Monteiro</surname><given-names>Olivia</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114898"><name><surname>Buettner</surname><given-names>Sven</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114892"><name><surname>Meyer</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108013"><name><surname>Bano</surname><given-names>Daniele</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114893"><name><surname>Radyushkin</surname><given-names>Konstantin</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-48307"><name><surname>Langston</surname><given-names>Rosamund</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114894"><name><surname>Lambert</surname><given-names>Jeremy J</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3454"><name><surname>Wanker</surname><given-names>Erich</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8072-1630</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-114895"><name><surname>Methner</surname><given-names>Axel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8774-0057</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-114896"><name><surname>Krauss</surname><given-names>Sybille</given-names></name><email>Sybille.krauss@dzne.de</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-114897"><name><surname>Schweiger</surname><given-names>Susann</given-names></name><email>schweigs@uni-mainz.de</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-40201"><name><surname>Stroh</surname><given-names>Albrecht</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9410-4086</contrib-id><email>albrecht.stroh@unimedizin-mainz.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Institute of Pathophysiology, Focus Program Translational Neurosciences</institution><institution>University Medical Center</institution><addr-line><named-content content-type="city">Mainz</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Institute for Human Genetics</institution><institution>University Medical Center</institution><addr-line><named-content content-type="city">Mainz</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution>German Center for Neurodegenerative Diseases (DZNE)</institution><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department for Neurology</institution><institution>University Medical Center</institution><addr-line><named-content content-type="city">Mainz</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Division of Neurosciences</institution><institution>Ninewells Hospital and Medical School</institution><addr-line><named-content content-type="city">Dundee</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Mouse Behavior Unit</institution><institution>University Medical Center</institution><addr-line><named-content content-type="city">Mainz</named-content></addr-line><country>Germany</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Department of Neuroproteomics</institution><institution>Max-Delbrück-Center</institution><addr-line><named-content content-type="city">Berlin</named-content></addr-line><country>Germany</country></aff></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib2"><label>‡</label><p>These authors also contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>04</day><month>09</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e38744</elocation-id><history><date date-type="received" iso-8601-date="2018-05-29"><day>29</day><month>05</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-09-02"><day>02</day><month>09</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Arnoux et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Arnoux et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-38744-v3.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.38744.001</object-id><p>Catching primal functional changes in early, ‘very far from disease onset’ (VFDO) stages of Huntington’s disease is likely to be the key to a successful therapy. Focusing on VFDO stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing <italic>in vivo</italic> two-photon Ca<sup>2+</sup> imaging, we revealed an early pattern of circuit dysregulation in the visual cortex - one of the first regions affected in premanifest Huntington’s disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are accompanied by aberrations in animal behavior. We furthermore show that the antidiabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both early network activity patterns and behavioral aberrations. This network-centered approach reveals a critical window of vulnerability far before clinical manifestation and establishes metformin as a promising candidate for a chronic therapy starting early in premanifest Huntington’s disease pathogenesis long before the onset of clinical symptoms.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.38744.002</object-id><title>eLife digest</title><p>Huntington’s disease is a devastating brain disorder that causes severe mood disorders, problems with moving, and dementia. Most people develop the condition between their thirties and fifties, and die a decade or two after the symptoms first appear.</p><p>The disease emerges because of a mutation in the gene for the Huntingtin protein, which leads to neurons slowly dying in the brain. While genetic testing can reveal who carries the faulty gene, no treatment addresses the root of the disorder or prevents it from appearing. Instead, most therapies for Huntington’s disease aim to reduce brain damage once the telltale symptoms are already present. However, the disease-causing protein is expressed early during the life of a patient, which could give it time to damage the brain long before neurons die and the disorder reveals itself. Treatments that start after the first signs of the disease may be too late to reverse the damage. Detecting and preventing early brain changes in people that carry the mutation may thus help to stop the disease from progressing.</p><p>Here, Arnoux, Willam, Griesche et al. set out to detect the minute changes that the faulty Huntingtin protein may cause in the brain network of young mice with the mutation. State-of-the-art imaging tools helped to examine individual neurons in the brain area that processes visual information. These experiments revealed that a group of brain cells had become hyperactive; once this change had occurred, the mutant animals were less anxious than is typical for mice.</p><p>Metformin is a drug used to treat diabetes, but it also interferes with a structure that is required to produce the disease-causing Huntingtin protein. Arnoux et al. therefore explored whether the compound could rescue the early brain alterations observed in mutant mice. Adding metformin in the water of the animals for three weeks halted the production of the mutant protein, reversed the brain changes and stopped the abnormal behavior.</p><p>Further work is now required in humans to confirm that Huntington’s disease starts with a change in the activity of networks in the brain, and to verify that metformin can stop the disorder in its track.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Huntington disease</kwd><kwd>in vivo calcium imaging</kwd><kwd>cortical microcircuits</kwd><kwd>neuronal hyperactivity</kwd><kwd>metformin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>C. elegans</italic></kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>European Huntington's Disease Network</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Methner</surname><given-names>Axel</given-names></name><name><surname>Stroh</surname><given-names>Albrecht</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Focus Program Translational Neuroscience</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Arnoux</surname><given-names>Isabelle</given-names></name><name><surname>Willam</surname><given-names>Michael</given-names></name><name><surname>Methner</surname><given-names>Axel</given-names></name><name><surname>Schweiger</surname><given-names>Susann</given-names></name><name><surname>Stroh</surname><given-names>Albrecht</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>BMBF Eurostars</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Arnoux</surname><given-names>Isabelle</given-names></name><name><surname>Stroh</surname><given-names>Albrecht</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000723</institution-id><institution>Tenovus</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lambert</surname><given-names>Jeremy J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In a premanifest mouse model of Huntington's disease at a stage very far from disease onset, significant network and behavior dysregulation was found, being rebalanced by treatment with metformin.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Huntington’s disease is caused by the expansion of a CAG repeat in the open-reading frame of the huntingtin gene (<italic>HTT</italic>), which translates into an expanded glutamine stretch in the aberrant, mutant protein (mHTT). Huntington’s disease has primarily been described as a late-onset neurodegenerative disease. However, it is preceded in its premanifest period by a prolonged presymptomatic phase followed by a prodromal phase with hardly detectable and unspecific symptoms occurring far before classical Huntington’s disease becomes apparent (<xref ref-type="bibr" rid="bib59">Ross et al., 2014</xref>). These symptoms include reduced impulse control, social disengagement, low conversational participation, reduction of the concentration span and decline of clearly defined cognitive domains (<xref ref-type="bibr" rid="bib65">Stout et al., 2011</xref>; <xref ref-type="bibr" rid="bib56">Predict-HD Investigators of the Huntington Study Group et al., 2007</xref>; <xref ref-type="bibr" rid="bib59">Ross et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">Labuschagne et al., 2016</xref>) and are accompanied by slight changes of cortical network topology and functional connectivity in resting state fMRI measures (<xref ref-type="bibr" rid="bib57">PREDICT-HD investigators of the Huntington Study Group et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Wolf et al., 2012</xref>). Importantly, such subtle network dysregulations may occur even earlier than the described prodromal symptoms in a very far from disease onset (VFDO) premanifest stage (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). This stage reaches back more than 15–20 years before motor symptoms become visible in patients and far before protein aggregates and neurodegeneration are observed.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.38744.003</object-id><label>Figure 1.</label><caption><title><italic>In vivo</italic> two-photon Ca<sup>2+</sup> imaging in layer 2/3 of visual cortex reveals a hyperactive neuronal activity pattern prior to disease onset.</title><p>(<bold>a,b</bold>) Top right, Illustrations indicating the visual cortex (blue area) in human (<bold>a</bold>) and mouse (<bold>b</bold>) brains. The brains are not drawn to scale. Bottom, timeline of Huntington’s disease progression in human and Hdh150 mouse model of Huntington’s disease. The Huntington’s disease onset was age 30–50 years in humans and ~70 weeks in Hdh150 mice. We conducted our experiments during a very early pre-symptomatic phase, far prior to mHtt aggregates and motor symptoms. VFDO: very far from disease onset. (<bold>c</bold>) Representative two-photon images of OGB-1 AM staining in layer 2/3 of the visual cortex of WT and Hdh150 mice. Scale bar: 70 µm. (<bold>d</bold>) Color-coded maps of silent (black) and spontaneously active (orange) neurons in WT (left) and Hdh150 (right) mice. Dashed lines represent the boundaries of blood vessels (original images in <xref ref-type="fig" rid="fig1">Figure 1c</xref>). Scale bar: 100 µm. (<bold>e</bold>) Density of stained cells in layer 2/3 of the visual cortex in WT and Hdh150 mice. Unpaired t-test, p=0.71. (<bold>f</bold>) Increased proportion of spontaneously active neurons in Hdh150 mice. Unpaired t-test, p&lt;0.05. (<bold>g</bold>) Representative traces of spontaneous Ca<sup>2+</sup> transients (red) of 10 neurons recorded in vivo in WT and Hdh150 mice. Vertical scale bars: 40% dF/F. (<bold>h</bold>) Increased frequency of Ca<sup>2+</sup> transients in spontaneously active neurons of Hdh150 mice. Silent neurons were excluded, as in subsequent panels. Mann-Whitney test, p&lt;0.01 (<bold>i</bold>) Quantification of area under the curve (AUC) of Ca<sup>2+</sup> transients. Unpaired t-test, p=0.98 (<bold>j</bold>) Cumulative frequency distribution of Ca<sup>2+</sup> transients in WT (dark grey) and Hdh150 (red) mice. Top, colored categorization of neurons according to their Ca<sup>2+</sup> transient frequencies. Two-way ANOVA, group: p&lt;0.0001, time: p&lt;0.0001, Interaction: p&lt;0.0001. (<bold>k</bold>) Color-coded categorization of neurons according to their Ca<sup>2+</sup> transient frequency: ‘low’ (&lt;0.3 trans/min, blue; silent neurons excluded), ‘medium’ (0.3–3 trans/min, orange) and ‘hyper’ (&gt;3 trans/min, red). Each peak is marked by an asterisk. (<bold>l</bold>) Relative proportion of low, medium and hyperactive neurons in layer 2/3 of the visual cortex in WT (left) and Hdh150 (right) mice. Chi-square test, p&lt;0.01.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.38744.007</object-id><label>Figure 1—source data 1.</label><caption><title>Numerical values of <xref ref-type="fig" rid="fig1">Figure 1</xref> and associated supplement figures.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38744-fig1-data1-v3.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><object-id pub-id-type="doi">10.7554/eLife.38744.008</object-id><label>Figure 1—source data 2.</label><caption><title>Code used for the analysis of calcium imaging.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-38744-fig1-data2-v3.zip"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig1-v3"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Ca<sup>2+</sup> events from astrocytes and neurons show clearly distinct kinetics.</title><p>(<bold>a</bold>) Schematic diagram of the two-photon microscope used for high-speed Ca<sup>2+</sup> imaging <italic>in vivo</italic>. The synthetic dye OGB-1 AM loaded in layer 2/3 of mouse visual cortex was excited by pulsed laser light generated by a Ti:sapphire laser (λ = 800 nm), a resonant scanner enabled video-rate imaging. Emitted light was collected by a photomultiplier tube (PMT). (<bold>b</bold>) Two-photon images of OGB-1 AM staining captured <italic>in vivo</italic> at depths between 150 and 270 µm from the pial surface in the visual cortex of WT (top) and Hdh150 (bottom) mice. Scale bar: 70 µm. (<bold>c</bold>) Two-photon image of OGB-1 AM staining in layer 2/3 of the visual cortex. Neurons (open squares) show round shapes with no processes. Astrocytes (inverted open triangle) in contrast, are more intensely stained; both the soma and processes can be visualized. Scale bar: 40 µm. (<bold>d</bold>) Five representative traces recorded for visually identified neurons (left) and astrocytes (right). Putative astrocytes show slower rise time, longer duration, and slower decay. The onset of events is aligned. Scale bars: 40% dF/F. (<bold>e, f</bold>) Box-and-whisker plots displaying the time to peak (<bold>e</bold>) and decay time (<bold>f</bold>) in neurons and astrocytes. Mann-Whitney test, p&lt;0.01. .</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig1-figsupp1-v3"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Cortical hyperactivity is independent of mHtt aggregation, astrogliosis or apoptotic cell death in presymptomatic VFDO Hdh150 mice.</title><p>(<bold>a, b, c</bold>) Confocal images of sagittal or coronal sections of 13 weeks old WT and Hdh150 mice stained for Htt proteins (<bold>a</bold>), glial fibrillary acidic protein (GFAP, (<bold>b</bold>)) and neuronal (NeuN, (<bold>c</bold>)) and apoptotic markers (cleaved-caspase 3, (<bold>c</bold>), arrows). Scale bars: 20 (<bold>a</bold>), 200 (<bold>b</bold>) and 100 (<bold>c</bold>) µm.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig1-figsupp2-v3"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.006</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Randomization of experimental data to assess specific spatial clustering.</title><p>(<bold>a,b</bold>) Color-coded spatial distributions and raster plots of the peak of Ca<sup>2+</sup> transients in low (blue), medium (orange) and hyperactive (red) neurons recorded <italic>in vivo</italic> in layer 2/3 of the visual cortex ((<bold>a</bold>), left) and after randomization of the data ((<bold>b</bold>), right). Silent cells are also displayed in the color-coded maps (black). (<bold>c</bold>) Color-coded spatial distribution of silent (black), low (blue), medium (orange) and hyperactive (red) neurons in WT (left) and Hdh150 (right) mice. The maps are equivalent to <xref ref-type="fig" rid="fig1">Figure 1d</xref>, but active neurons were subdivided into groups based on Ca<sup>2+</sup> transient frequency. Dashed line outlines the boundary of blood vessels. Scale bar: 100 µm. (<bold>d</bold>) Box-and-whisker plot showing the mean pairwise distance for the different type of neuronal pairs (SS: silent-silent, SL: silent-low, SM: silent-medium, SH: silent-hyper, LL: low-low, LM: low-medium, LH: low-hyper, MM: medium-medium, MH: medium-hyper, HH: hyper-hyper) in WT (filled dark grey) and Hdh150 (filled red) mice. The experimental data were compared to randomized data (WT rand and Hdh150 rand, open dark grey and red, respectively). No significant difference was observed between groups in WT and Hdh150 mice. This indicated an absence of spatial clustering among any of the subgroups of active neurons. Mann-Whitney test, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig1-figsupp3-v3"/></fig><media id="fig1video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-38744-fig1-video1.mp4"><object-id pub-id-type="doi">10.7554/eLife.38744.009</object-id><label>Figure 1—video 1.</label><caption><title><italic>In vivo</italic> two-photon images of mouse visual cortex performed at different depths (indicated in the upper left corner) after multi-bolus loading with OGB-1 AM.</title><p>Scale bar: 50 µm.</p></caption></media><media id="fig1video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-38744-fig1-video2.mp4"><object-id pub-id-type="doi">10.7554/eLife.38744.010</object-id><label>Figure 1—video 2.</label><caption><title>Representative time-lapse of <italic>in vivo</italic> two-photon Ca<sup>2+</sup> imaging acquired in layer 2/3 of mouse visual cortex showing single-cell Ca<sup>2+</sup> transients.</title><p>Scale bar: 40 µm.</p></caption></media></fig-group><p>In Huntington’s disease occurrence of such very early changes is supported by the observation of early deficits in premanifest Huntington’s disease mutation carriers, such as loss of phosphodiesterase 10A in the occipital lobe up to 47 years prior to disease onset (summarized in <xref ref-type="bibr" rid="bib70">Wilson et al., 2017</xref>). Also, the ability to perform complex visuospatial orientation, such as visual search, seems to be altered even in pre-manifest stages far from clinical diagnosis (<xref ref-type="bibr" rid="bib41">Labuschagne et al., 2016</xref>). We hypothesize that primal functional changes in the VFDO stage of premanifest Huntington’s disease open up very early vulnerable windows for disease development and preventive therapy prior to neuronal loss and may also provide promising early biomarkers for therapy development (<xref ref-type="bibr" rid="bib45">Mehler and Gokhan, 2000</xref>; <xref ref-type="bibr" rid="bib34">Kerschbamer and Biagioli, 2015</xref>; <xref ref-type="bibr" rid="bib28">Humbert, 2010</xref>; <xref ref-type="bibr" rid="bib7">Cepeda et al., 2003</xref>).</p><p>It seems that the visual cortex is one of the first regions that are functionally affected during disease development in Huntington’s disease (<xref ref-type="bibr" rid="bib41">Labuschagne et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Dogan et al., 2013</xref>). In order to identify primal network changes, we have here established a network-centered approach and focused on microcircuit function in layer 2/3 of the visual cortex at an early premanifest stage in a mouse model of Huntington’s disease corresponding to the VFDO stage in premanifest Huntington’s disease. We have used two-photon imaging using fluorescent indicators of intracellular Ca<sup>2+</sup> in order to resolve the functional architecture of intact cortical microcircuits <italic>in vivo</italic> with single neuron resolution (<xref ref-type="bibr" rid="bib20">Grienberger and Konnerth, 2012</xref>). We show that even at the early age of 10 – 15 weeks (young adults compared to humans), the entire cortical microcircuit shifts towards a more excitable state characterized by a complex change in neuronal activity pattern and hyperactive neurons. These findings are accompanied by changes in animal behavior, including a decrease in anxiety.</p><p>No effective and curative treatment has been developed for Huntington’s disease so far (<xref ref-type="bibr" rid="bib18">Frank, 2014</xref>). A chronic drug therapy that commences early on in VFDO stages in premanifest Huntington’s disease and ameliorates early dysregulations as the potential origin of pathogenic processes and disease spreading is therefore a promising and necessary strategy. In Huntington’s disease animal models, even short-term reduction of protein load through RNA interference and antisense strategies has beneficial effects on disease phenotypes and progression lasting several months after intervention (<xref ref-type="bibr" rid="bib63">Stanek et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">DiFiglia et al., 2007</xref>; <xref ref-type="bibr" rid="bib32">Keiser et al., 2016</xref>). We have recently shown that mRNAs carrying CAG repeats bind to a protein complex containing the ubiquitin ligase midline 1 (MID1) in a repeat size-dependent manner. Through ubiquitination MID1 regulates PP2A (protein phosphatase 2A) and mTOR (mechanistic target of rapamycin) activities and the translation of associated mRNAs (<xref ref-type="bibr" rid="bib38">Krauss et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">Griesche et al., 2016</xref>). Disruption of the MID1/PP2A/mTOR protein complex leads to an increase of PP2A activity, a decrease of mTOR activity and a reduction of translation rates of mRNAs with expanded CAG repeats (<xref ref-type="bibr" rid="bib38">Krauss et al., 2013</xref>).</p><p>We show here that the type II diabetes drug metformin interferes with the MID1/PP2A/mTOR protein complex and significantly reduces the translation rate of <italic>Htt</italic> mRNA, resulting in a reduction of aberrant Htt protein production <italic>in vitro</italic> and <italic>in vivo</italic> in the Hdh150 mouse model. Notably, in Hdh150 mice <italic>in vivo</italic> metformin, when given early in the VFDO stage, and chronically in the drinking water, fully reverses both early neuronal network dysregulations and behavioral aberrations.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Increase in cortical neuronal network activity in presymptomatic Huntington’s disease mice</title><p>Since the visual cortex is one of the first regions affected by the disease (<xref ref-type="bibr" rid="bib14">Dogan et al., 2013</xref>; <xref ref-type="bibr" rid="bib41">Labuschagne et al., 2016</xref>), we focused on layer 2/3 of the visual cortex of ∼12 weeks old, heterozygous knock-in mice expressing expanded Htt with 150 glutamine repeats (Hdh150), in the lightly anesthetized mouse. This time corresponds to the VFDO in presymptomatic Huntington’s disease (<xref ref-type="fig" rid="fig1">Figure 1a,b</xref>). We focused our analysis on male mice, thereby minimizing the influence of hormonal fluctuations on network activity. This approach is in line with a recent study in the field of Alzheimer’s disease (<xref ref-type="bibr" rid="bib29">Iaccarino et al., 2016</xref>), using males only. We employed two-photon Ca<sup>2+</sup> imaging <italic>in vivo</italic> using the synthetic Ca<sup>2+</sup> indicator Oregon-Green BAPTA1 (OGB-1) AM to monitor the suprathreshold activity of a neuronal microcircuit with cellular resolution, typically comprising around 200 neurons (<xref ref-type="bibr" rid="bib33">Kerr et al., 2005</xref>) (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a,b</xref>). Events from astrocytes, which are also stained by OGB-1, were excluded from this neuronal network based on their temporal dynamics (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1c–f</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p><p>By imaging at different depths, we found a similar spatial extent of OGB-1 staining in the visual cortex of Hdh150 and control wild-type (WT) mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>). <xref ref-type="video" rid="fig1video1">Figure 1—video 1</xref> shows two-photon images acquired from the pial surface illustrating a homogenous OGB-1 staining in layers 1, 2 and 3 of mouse visual cortex. We observed no difference in the density of stained cells (<xref ref-type="fig" rid="fig1">Figure 1c and e</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, WT: 1413 ± 74 cells/mm<sup>2</sup> (n = 11 mice), Hdh150 1456 ± 90 cells/mm<sup>2</sup> (n = 10 mice), Mann-Whitney test p=0.8).</p><p>To identify changes in microcircuit activity, we assessed spontaneous activity <italic>in vivo</italic> in the cortical microcircuit of WT and Hdh150 mice, which reliably reflects the functional microarchitecture of sensory cortical areas (<xref ref-type="bibr" rid="bib48">Miller et al., 2014</xref>). <xref ref-type="video" rid="fig1video2">Figure 1—video 2</xref> shows an example of <italic>in vivo</italic> two-photon Ca<sup>2+</sup> imaging exhibiting ongoing spontaneous activity in layer 2/3 of mouse visual cortex with single-cell resolution. Both WT and Hdh150 mice exhibited silent and active cells (<xref ref-type="fig" rid="fig1">Figure 1d</xref>), but a significantly higher proportion of active neurons was detected in Hdh150 mice, indicating a more active network (<xref ref-type="fig" rid="fig1">Figure 1f</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, WT: 65.1 ± 3.5% (n = 8 mice), Hdh150: 77.1 ± 3.5% (n = 6 mice), unpaired t-test p&lt;0.05). No spatial clustering of silent or active cells could be observed in either group (<xref ref-type="fig" rid="fig1">Figure 1d</xref>).</p><p>Next, we analyzed the frequency of Ca<sup>2+</sup> transients and activity patterns in the population of active neurons (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). Notably, the frequency of Ca<sup>2+</sup> transients was significantly higher in Hdh150 compared to WT mice (<xref ref-type="fig" rid="fig1">Figure 1g–h</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, WT: 0.74 ± 0.06 trans/min (n = 8 mice), Hdh150: 1.2 ± 0.14 trans/min (n = 6 mice), Mann-Whitney test, p&lt;0.01). No difference was found in the mean area under the curve (AUC) of Ca<sup>2+</sup> transients between WT and Hdh150 mice (<xref ref-type="fig" rid="fig1">Figure 1i</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, WT: 39.8 ± 3.9 (dF/f)*s, Hdh150: 39.9 ± 3.6 (dF/f)*s, unpaired t-test, p=0.98) indicating that on average, the mean number of underlying action potentials for each individual calcium transient was not different in Hdh150 mice.</p><p>We furthermore analyzed the distribution of neurons according to their Ca<sup>2+</sup> transient frequency. The cumulative probability distribution of the activity of individual neurons in Huntington’s disease mice was shifted toward higher frequencies indicating that the overall neuronal activity transitioned toward a more excitable network (<xref ref-type="fig" rid="fig1">Figure 1j</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, two-way ANOVA p&lt;0.0001). We sub-classified the active neurons into three functional subgroups according to their transient frequency: low, medium and hyperactive (<xref ref-type="fig" rid="fig1">Figure 1k</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Notably, we identified a unique subgroup in VFDO Hdh150 mice: hyperactive neurons (<xref ref-type="fig" rid="fig1">Figure 1l</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, Chi-square test p&lt;0.01). This subgroup was accompanied by a reduction in the number of neurons with low activity, which corroborates the shift of the microcircuit activity.</p><p>In later stages of Alzheimer’s disease, hyperactive cells were shown to cluster near amyloid plaques (<xref ref-type="bibr" rid="bib2">Busche et al., 2008</xref>). A similar scenario might occur in Huntington’s disease. To clarify whether the cortex of VFDO Hdh150 mice is affected by mHtt aggregates - a later stage Huntington’s disease hallmark - we performed immunohistochemistry in Hdh150 and WT animals. We observed only diffuse and non-aggregated Htt immunoreactivity in the cytoplasm of neurons in cortical areas of both WT and Hdh150 mice (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a</xref>) in accordance with previous studies (<xref ref-type="bibr" rid="bib42">Lin et al., 2001</xref>). In addition, no reactive astrocytes were observed (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2b</xref>) and only few cells that were stained for activated caspase-3, an apoptotic marker, in cortical areas of WT and Hdh150 mice (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2c</xref>) as previously observed (<xref ref-type="bibr" rid="bib73">Yu et al., 2003</xref>). In order to test whether hyperactive cells cluster in the Hdh150 mouse model, spatial distance between every pair of neurons was quantified (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3c,d</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). We observed no significant differences between the permutations of functional subgroups in premanifest Hdh150 and control mice, reflecting a rather homogenous distribution of all functional subgroups (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3c,d</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, Mann-Whitney, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values). This finding was confirmed in randomized data in which cell location was kept but functional identity was randomly permutated (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a,b and d</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Taken together, clustering of hyperactive cells could not be observed in VFDO Hdh150 animals and cortical hyperactivity is independent of mHtt aggregation, apoptotic cell death or astrogliosis at this presymptomatic VFDO stage.</p><table-wrap id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.38744.011</object-id><label>Table 1.</label><caption><title>Statistics</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Figure</th><th>Test</th><th>Values</th><th>N</th></tr></thead><tbody><tr><td><xref ref-type="fig" rid="fig1">Figure 1e</xref></td><td>Unpaired t test, two-tailed</td><td>NS, p=0.71</td><td>WT n = 11 mice; Hdh150 n = 10 mice</td></tr><tr><td><xref ref-type="fig" rid="fig1">Figure 1f</xref></td><td>Unpaired t test, two-tailed</td><td>p=0.023</td><td>WT n = 1204 cells in eight mice; <break/>Hdh150 n = 933 cells in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig1">Figure 1h</xref></td><td>Mann-Whitney test</td><td>p=0.006</td><td>WT n = 765 cells in eight mice; <break/>Hdh150 n = 695 cells in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig1">Figure 1i</xref></td><td>Unpaired t test, two-tailed</td><td>NS, p=0.98</td><td>WT n = 765 cells in eight mice; <break/>Hdh150 n = 695 cells in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig1">Figure 1j</xref></td><td>Two-way ANOVA test</td><td>Group: p&lt;0.0001, Df = 1, F = 85.96, time: p&lt;0.0001, Df = 16, F = 147, Interaction: p&lt;0.0001, F = 4.9, Df = 16</td><td>WT n = 765 cells in eight mice; <break/>Hdh150 n = 695 cells in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig1">Figure 1l</xref></td><td>Chi-square test</td><td>p=0.002, df = 1, Chi-square = 9.127</td><td>WT n = 765 cells in eight mice; <break/>Hdh150 n = 695 cells in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig2">Figure 2b</xref></td><td>Mann-Whitney test</td><td>WT vs Hdh150 p=0.03; WT vs WT rand p&lt;0.0001; Hdh150 vs Hdh150 rand p&lt;0.0001</td><td>WT n = 26126 Pearson's r in eight <break/>mice; Hdh150 n = 58050 Pearson's <break/>r in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig2">Figure 2c</xref></td><td>Mann-Whitney test</td><td>WT vs Hdh150 mice: MM p=0.041 in Hdh150 mice; compared to LL: MM p=0.0496, MH p=0.005, HH p=0.009</td><td>WT n = 26126 Pearson's r in eight <break/>mice; Hdh150 n = 58050 <break/>Pearson's r in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig2">Figure 2d</xref></td><td>Two-way ANOVA test</td><td>Group: p&lt;0.0001, Df = 1, F = 58.20 <break/>Distance: p=0.97, Df = 15, F = 0.44 <break/>Interaction: p=0.33, df = 15, F = 1.13</td><td>WT n = 26126 distances in <break/>eight mice; Hdh150 n = 58050 distances in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig2">Figure 2e</xref></td><td>Two-way ANOVA test</td><td>p=0.35, Df = 1, F = 0.86</td><td>WT rand n = 26126 distances <break/>in eight mice; Hdh150 rand <break/>n = 58050 distances in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig3">Figure 3b</xref></td><td>Mann-Whitney test</td><td>p=0.031119</td><td>WT n = 10 mice; Hdh150 n = 13 mice</td></tr><tr><td><xref ref-type="fig" rid="fig4">Figure 4a</xref></td><td>Mann-Whitney test</td><td>control vs 1 mM metformin p=0.084521, control vs 2.5 mM metformin p=0.023231</td><td>Control n = 10, 1 mM metformin <break/>n = 11, 2.5 mM metformin n = 10.</td></tr><tr><td><xref ref-type="fig" rid="fig4">Figure 4b</xref></td><td>Mann-Whitney test</td><td>control siRNA vs MID1 siRNA p=0.008, control siRNA vs MID1 siRNA + metformin p=0.015</td><td>Control siRNA n = 6, MID1 siRNAn = 6, MID1 siRNA + metformin n=6.</td></tr><tr><td><xref ref-type="fig" rid="fig4">Figure 4c</xref></td><td>RM two-way ANOVA</td><td>Treatment: p=0.0082, Df = 2, F = 5 <break/>Time: p&lt;0.0001, Df = 47, F = 27.5 <break/>Interaction: p&lt;0.0001, Df = 94, F = 5.9</td><td>n<sub>control</sub> = 47, n<sub>metformin 1mM</sub> = 44, <break/>n<sub>metformin 2.5mM</sub> = 35</td></tr><tr><td><xref ref-type="fig" rid="fig4">Figure 4d</xref></td><td>RM two-way ANOVA</td><td>Treatment: p=0.0021, Df = 3, F = 5.1 <break/>Time: p&lt;0.0001, Df = 47, F = 64.1 <break/>Interaction: p&lt;0.0001, Df = 141, F = 6.1 p&lt;0.0001</td><td>n<sub>control</sub> = 46, n<sub>metformin</sub> = 49, <break/>n<sub>metformin+OA</sub> = 51, n<sub>OA</sub> = 43</td></tr><tr><td><xref ref-type="fig" rid="fig4">Figure 4f</xref></td><td>Unpaired t-test</td><td>p=0.0473</td><td>Hdh150 n = 6; Hdh150 <break/>metformin n = 6</td></tr><tr><td><xref ref-type="fig" rid="fig4">Figure 4h</xref></td><td>Unpaired t-test</td><td>p=0.0467</td><td>Hdh150 n = 3; Hdh150 <break/>metformin n = 3</td></tr><tr><td><xref ref-type="fig" rid="fig4">Figure 4i</xref></td><td>Unpaired t-test</td><td>p=0.0062</td><td>Hdh150 n = 3; Hdh150 <break/>metformin n = 3</td></tr><tr><td><xref ref-type="fig" rid="fig4">Figure 4j</xref></td><td>Unpaired t-test</td><td>p=0.8766</td><td>Hdh150 n = 3; Hdh150 <break/>metformin n = 3</td></tr><tr><td><xref ref-type="fig" rid="fig5">Figure 5b</xref></td><td>Mann-Whitney test</td><td>WT vs Hdh150 p=0.023, Hdh150 vs Hdh150 met p=0.03, Hdh150 vs WT met p=0.012</td><td>WT n = 1204 cells in eight mice; <break/>Hdh150 n = 933 cells in six mice; <break/>WT met n = 1915 cells in nine mice; <break/>Hdh150 met n = 1585 cells in <break/>six mice</td></tr><tr><td><xref ref-type="fig" rid="fig5">Figure 5c</xref></td><td>Mann-Whitney test</td><td>WT vs Hdh150 p=0.006; Hdh150 vs Hdh150 met p=0.007; Hdh150 vs WT met p=0.008</td><td>WT n = 765 cells in eight mice; <break/>Hdh150 n = 695 cells in six mice; <break/>WT met n = 1199 in nine mice; <break/>Hdh150 met n = 1014 cells in <break/>six mice</td></tr><tr><td><xref ref-type="fig" rid="fig5">Figure 5d</xref></td><td>Two-way ANOVA test</td><td>Group: p&lt;0.0001, Df = 3, F = 61.80 <break/>Time: p&lt;0.0001, Df = 16, F = 345.9 <break/>Interaction: p&lt;0.0001, Df = 48, F = 3.64</td><td>WT n = 765 cells eight mice; <break/>Hdh150 n = 695 cells six mice; <break/>WT met n = 1199 cells nine mice; <break/>Hdh150 met n = 1012 cells six <break/>mice</td></tr><tr><td><xref ref-type="fig" rid="fig5">Figure 5e</xref></td><td>Chi-square test</td><td>p=0.62, df = 1; Chi-square = 0.24</td><td>WT n = 765 cells eight mice; <break/>Hdh150 n = 695 cells six mice; <break/>WT met n = 1199 cells nine mice; <break/>Hdh150 met n = 1012 cells six mice</td></tr><tr><td><xref ref-type="fig" rid="fig5">Figure 5f</xref></td><td>Mann-Whitney test</td><td>WT vs Hdh150 p=0.03; Hdh150 vs Hdh150 met p=0.002; Hdh150 vs WT met p=0.003</td><td>WT n = 765 cells eight mice; <break/>Hdh150 n = 695 cells six mice; <break/>WT met n = 1199 cells nine mice; <break/>Hdh150 met n = 1012 cells six mice</td></tr><tr><td><xref ref-type="fig" rid="fig5">Figure 5g</xref></td><td>Two-way ANOVA test</td><td>Group: p&lt;0.0001, Df = 3, F = 85.96 <break/>Distance: p=0.99, Df = 45, F = 0.58 <break/>Interaction: p=0.0007, Df = 15, F = 2.63</td><td>WT n = 765 cells eight mice; <break/>Hdh150 n = 695 cells six mice; <break/>WT met n = 1199 cells nine mice; <break/>Hdh150 met n = 1012 cells six mice</td></tr><tr><td><xref ref-type="fig" rid="fig5">Figure 5i</xref></td><td>Mann-Whitney test</td><td>WT vs Hdh150 p=0.002, Hdh150 vs Hdh150 Met p=0.002, Hdh150 vs. WT met p=0.02, WT vs Hdh150 Met p=0.82</td><td>WT n = 10; Hdh150 n = 13; WT <break/>met n = 6; Hdh150 met n = 8 mice</td></tr><tr><td>Figures supplements</td><td>Test</td><td>values</td><td>n</td></tr><tr><td><xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1e</xref></td><td>Mann-Whitney test</td><td>p=0.002</td><td>n = 6 neurons, n = 6 astrocytes</td></tr><tr><td><xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1f</xref></td><td>Mann-Whitney test</td><td>p=0.002</td><td>n = 6 neurons, n = 6 astrocytes</td></tr><tr><td><xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3d</xref></td><td>Mann-Whitney test</td><td>In WT mice: SS vs SL p=0.5, SS vs SM p=0.9, SS vs LL p=0.1, SS vs LM p=0.2, SS vs MM p=0.1, SL vs SM p=0.4, SM vs LL p=0.1, SM vs MM p=0.1, LL vs MM p=0.9, LM vs MM p=0.4, LM vs SM, p=0.2. <break/>In Hdh150 mice: SS vs SL p=0.8, SS vs SM p=0.5, SS vs SH p=0.9, SS vs SH p=0.9, SS vs LL p=0.9, SS vs LM p=0.9, SS vs LH p=1, SS vs MM p=0.1, SS vs MH p=0.1, SS vs HH p=0.4, SL vs SM p=0.8, SL vs SH p=0.9, SL vs LL p=0.9, SL vs LM p=0.9, SL vs LH p=0.8, SL vs MM p=0.5, SL vs MH p=0.6, SL vs HH p=0.7, SN vs SH p=0.6, SM vs LL p=0.7, SM vs LM p=0.6, SN vs LH p=0.4, SM vs MM p=0.3, SN vs MH p=0.4, SN vs HH p 0 0.6, SH vs LL p=0.7, SH vs LM p=1, SH vs LH p=1, SH vs MM p=0.4, SH vs MH p=0.3, SH vs HH p=0.6, LL vs LM p=0.9, LL vs LH p=1, LL vs MM p=0.5, LL vs MH p=0.7, LL vs HH p=0.8, LM vs LH p=0.6, LM vs MM p=0.3, LM vs MH p=0.3, LM vs HH p=0.5, LH vs MM p=0.3, LH vs MH p=0.3, LH vs HH p=0.5, MM vs MH p=0.7, NN vs HH p=0.8, MH vs HH p=0.9 <break/>In WT vs WT rand: WT mice: SS p=0.5, SL p=0.7, SM p=0.3, LL p=0.3, LM p=0.8, MM p=0.1. <break/>In Hdh150 vs Hdh150 rand: SS p=0.6, SL p=1, SM p=1, SH p=0.6, LL p=0.7, LM p=0.6, LH p=0.2, MM p=0.6, MH p=0.8, HH p=0.7 NS</td><td>WT n = 72595 distances eight <break/>mice; Hdh150 n = 132009 <break/>distances six mice</td></tr><tr><td><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref></td><td>Mann-Whitney test</td><td>LL p=0.005; LM p&lt;0.0001; MM p&lt;0.0001</td><td>WT n = 26126 Pearson's r in eight mice</td></tr><tr><td><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref></td><td>Mann-Whitney test</td><td>LL p=0.004; LM p=0.0006; LH p=0.041; MM p&lt;0.0001; MH p=0.0002; HH p=0.01. In Hdh150 mice, compared to LL: MM p=0.049; MH p=0.005; HH p=0.009</td><td>Hdh150 n = 58050 Pearson's <break/>r in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2c</xref></td><td>Mann-Whitney test</td><td>routine p=0.4, leak p=0.5, CI p=0.6, CI + CII p=0.5, ETS p=0.2</td><td>WT n = 6 mice; Hdh150 <break/>n = 6 mice</td></tr><tr><td><xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b</xref></td><td>RM two-way ANOVA</td><td>Genotype: p=0.6, Df = 1, F = 0.3 <break/>Time: p&lt;0.0001, Df = 6, F = 86.1 <break/>Interaction: p=0.6, Df = 6, F = 0.7</td><td>WT n = 16 mice; Hdh150 <break/>n = 13 mice</td></tr><tr><td><xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1c</xref></td><td>RM two-way ANOVA</td><td>Genotype: p=0.5, Df = 1, F = 0.5 <break/>Time: p&lt;0.0001, Df = 9, F = 35.4 <break/>Interaction: p=0.03, Df = 9, F = 2.2</td><td>WT n = 16 mice; Hdh150 <break/>n = 13 mice</td></tr><tr><td><xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1d</xref></td><td>RM two-way ANOVA</td><td>Genotype: p=0.8, Df = 1, F = 3.4 <break/>Time: p&lt;0.01, Df = 6, F = 3.4 <break/>Interaction: p=0.97, Df = 6, F = 0.2</td><td>WT n = 16 mice; Hdh150 n = 13 mice</td></tr><tr><td><xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1e</xref></td><td>Mann-Whitney test</td><td>p=0.3</td><td>WT n = 10; Hdh150 n = 13; WT <break/>met n = 6; Hdh150 met n = 8 mice</td></tr><tr><td><xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref></td><td>RM two-way ANOVA</td><td>Treatment p=0.0342, Df = 2, F = 3.5; <break/>Time p&lt;0.0001, Df = 47, F = 45.3; Interaction p&lt;0.0001, Df = 94, F = 3.5</td><td>n<sub>control</sub> = 36, n<sub>metformin 1mM</sub> = 42, <break/>n<sub>metformin 2.5mM</sub> = 44</td></tr><tr><td><xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b</xref></td><td>RM two-way ANOVA</td><td>Treatment p=0.2986, Df = 1, F = 1.9; <break/>Time p=0.0654, Df = 20, F = 1.8; <break/>Interaction p=0.9988, Df = 20, F = 0.3.</td><td>control n = 7, metformin n = 8</td></tr><tr><td><xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1dc</xref></td><td>Unpaired t-test</td><td>p=0,1826</td><td>Hdh150 n = 4; Hdh150 metformin <break/>n = 4</td></tr><tr><td><xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2a</xref></td><td>Mann-Whitney test</td><td>p&lt;0.0001</td><td>control n = 65, metformin n = 65</td></tr><tr><td><xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2b</xref></td><td>Mann-Whitney test</td><td>Q40 vs. Q40 Met p&lt;0.0001</td><td>Q40n = 43, Q40 Met n = 43</td></tr><tr><td><xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2c</xref></td><td>Mann-Whitney test</td><td>Ctrl vs. 5 mM p=0.0078, Ctrl vs. 10 mM p&lt;0.0001</td><td>n = 45</td></tr><tr><td><xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2d</xref></td><td>Mann-Whitney test</td><td>p&lt;0.0001</td><td>Control n = 72, arc-1 RNAi n = 74</td></tr><tr><td><xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2e</xref></td><td>Mann-Whitney test</td><td>p&lt;0.0001</td><td>Control n = 60, arc-1 RNAi n = 62</td></tr><tr><td><xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1b</xref></td><td>Unpaired t test, two-tailed</td><td>WT met vs. Hdh150 met p=0.39, WT vs. WT met p=0.7, Hdh150 vs. Hdh150 met p=0.9</td><td>WT n = 11; Hdh150 n = 10; WT met <break/>n = 9; Hdh150 met n = 6 mice</td></tr><tr><td><xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1c</xref></td><td>Unpaired t test, two-tailed</td><td>WT vs WT met p=0.024</td><td>WT n = 765 cells eight mice; <break/>Hdh150 n = 695 cells six mice; <break/>WT met n = 1199 cells nine mice; Hdh150 <break/>met n = 1012 cells six mice</td></tr><tr><td><xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1d</xref></td><td>Unpaired t test, two-tailed</td><td>WT met: LL vs LM p=0.04 and LL vs MM p&lt;0.0001; Hdh150 met: LL vs LM p=0.4, LL vs MM p=0.004</td><td>WT met n = 57140 Pearson's r in <break/>nine mice; Hdh150 met n = 49535 <break/>Pearson's r in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1e</xref></td><td>Mann-Whitney test</td><td>LM WT vs LM Hdh150; MM WT vs MM Hdh150 p=0.04</td><td>WT n = 26126 Pearson's r in eight mice; <break/>Hdh150 n = 58050 Pearson's r in <break/>six mice; WT met n = 57140 <break/>Pearson's r in nine mice; Hdh150 <break/>met n = 49535 Pearson's r in six mice</td></tr><tr><td><xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1f</xref></td><td>Mann-Whitney test</td><td>SS p=0.1, SL p=0.1, SM p=0.1, LL p=0.4, LM p=0.3, MM p=0.2</td><td>WT met n = 140467 distances <break/>in nine mice; Hdh150 met <break/>n = 117485 distances in six mice</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Increased synchronicity and cortical dysfunction in premanifest VFDO Huntington’s disease mice</title><p>An important aspect of neuronal information processing is the optimization of encoding strategies. In the visual cortex, encoding of information is characterized by sparse and precisely timed neuronal activity. Cortical activity is defined by transiently co-active ensembles of neurons acting as a functional unit (<xref ref-type="bibr" rid="bib48">Miller et al., 2014</xref>). To capture these spatiotemporal dynamics in the microcircuit, we analyzed synchronicity of the transients between all pairs of neurons (<xref ref-type="fig" rid="fig2">Figure 2a</xref>) by calculating Pearson’s correlation coefficient (Pearson’s r) for every pair. First, we confirmed that the level of synchronicity within a healthy cortical microcircuit is drastically higher than the random synchronicity in shuffled data (<xref ref-type="fig" rid="fig2">Figure 2b</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>, WT: 0.024 ± 0.005, WT rand: −0.0003 ± 0.0003, Mann-Whitney test p&lt;0.0001). Notably, the synchronicity was even higher in Hdh150 mice compared to healthy controls (<xref ref-type="fig" rid="fig2">Figure 2b</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>, WT: 0.02 ± 0.005, Hdh150: 0.04 ± 0.006, Mann-Whitney test p&lt;0.05).</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.38744.012</object-id><label>Figure 2.</label><caption><title>Presymptomatic Hdh150 mice exhibit an increased synchronicity of cortical microcircuits.</title><p>(<bold>a</bold>) Color-coded Pearson’s r matrices calculated from representative recordings of WT (left) and Hdh150 (right) mice. Silent cells were excluded from the analysis. Right, color-coded scale of Pearson’s r values. (<bold>b</bold>) Overall Pearson’s correlation coefficient (Pearson's r) in WT (dark grey) and Hdh150 (red) mice for experimental (filled) and randomized (open) raster data. Mann-Whitney test, WT vs. Hdh150 p&lt;0.05; WT vs. WT rand p&lt;0.0001; Hdh150 vs. Hdh150 rand p&lt;0.0001 (<bold>c</bold>) Pearson’s r for combinations of neuronal pairs (LL: low-low, LM: low-medium, LH: low-hyper, MM: medium-medium, MH: medium-hyper, HH: hyper-hyper) in WT (dark grey) and Hdh150 (red) mice. * pairwise comparisons between a pair of WT and Hdh150 mice. <sup>#</sup> comparisons of functional subgroup pairs to the low-low pair within the same genotype. The pairs involving hyperactive neurons could only be analyzed in Hdh150 mice. Mann-Whitney test, WT vs. Hdh150 mice: MM p&lt;0.05 in Hdh150 mice; compared to LL: MM p&lt;0.05, MH p&lt;0.01, HH p&lt;0.01 (<bold>d,e</bold>) Relationship between Pearson’s r and distance between neuronal pairs in WT (black) and Hdh150 (red) mice (<bold>d</bold>) and randomized data (<bold>e</bold>). Lines represent the linear fit of WT and Hdh150 experimental data. Two-way ANOVA (<bold>d</bold>) Genotype: p&lt;0.0001 Distance: p=0.97, Interaction: p=0.3, (<bold>e</bold>) Genotype = 0.35, p=0.3, Interaction: p=0.8.</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.38744.015</object-id><label>Figure 2—source data 1.</label><caption><title>Numerical values of <xref ref-type="fig" rid="fig2">Figure 2</xref> and associated supplement figures.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38744-fig2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig2-v3"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.013</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Randomization of experimental data to assess specific network synchronicity.</title><p>(<bold>a,b</bold>) Comparison of Pearson’s r for different functional subgroup pairs in WT experimental and randomized data (<bold>a</bold>) and Hdh150 data (<bold>b</bold>), *p&lt;0.05, **p&lt;0.01 and ***p&lt;0.001, Mann-Whitney test. <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, in comparisons of functional subgroup pairs to the low-low pair within the same genotype.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig2-figsupp1-v3"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.014</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Presymptomatic Hdh150 mice did not exhibit alteration of mitochondria respiration.</title><p>(<bold>a,b</bold>) Scheme of the Oroboros O<sub>2</sub>K respirometer and typical traces obtained from high-resolution respirometry of microdissected cortical tissue from male WT or Hdh150 mice. (<bold>c</bold>) Box-and-whisker plot depicting the O<sub>2</sub> flow in n = 6 mice per genotype. No difference was observed indicating that mitochondria respiration is similar in the two genotypes. Mann-Whitney test, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig2-figsupp2-v3"/></fig></fig-group><p>Next, we compared the synchronicity level in all functional subgroups (<xref ref-type="fig" rid="fig2">Figure 2c</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). The pairs involving the low activity subgroups (LL and LM) showed no differences in WT and Hdh150 mice (Mann-Whitney test, in LL p=0.5 and in LM p=0.7). However, Pearson’s r increased significantly for the medium-to-medium (MM) pairs in Hdh150. Pearson’s r was even higher for medium-hyperactive (MH) and hyperactive-hyperactive (HH) compared to low-low (LL) pairs (Mann-Whitney test compared to LL in Hdh150 mice: in MM p&lt;0.05, in MH and HH p&lt;0.01).</p><p>To assess whether the increased synchronicity in the VFDO Hdh150 mice occurred merely due to the higher number of transients, we used randomized data with unchanged frequency but temporally shuffled transients (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a and b</xref>). Pearson’s r in the randomized data was nearly zero for all, including the high frequency subgroups in WT and Hdh150 mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a and b</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). This finding argued against the possibility that the increased Pearson's r in the experimental data occurred by chance.</p><p>We next asked whether functional ensembles with a high level of synchronicity are located in spatial vicinity to each other, by testing whether Pearson's r changed with physical distance between the pairs of neurons (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). An inverse linear relationship was observed between Pearson’s r and the pairwise distance in both the WT and Hdh150 mice (<xref ref-type="fig" rid="fig2">Figure 2d</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>, two-way ANOVA p&lt;0.0001, WT vs Hdh150) suggesting that two closely located neurons have a higher probability to fire together. This is consistent with similar findings in the forelimb motor cortex of head-restrained mice (<xref ref-type="bibr" rid="bib15">Dombeck et al., 2009</xref>). Randomization of the data abolished the inverse relationship between Pearson's r and distance (<xref ref-type="fig" rid="fig2">Figure 2e</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>, two-way ANOVA p=0.3, WT rand vs Hdh150 rand).</p><p>Since many studies, especially in premanifest mutation carriers, have linked Huntington’s disease pathology to changes in metabolism (<xref ref-type="bibr" rid="bib10">Damiano et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Duan et al., 2014</xref>; <xref ref-type="bibr" rid="bib31">Jin and Johnson, 2010</xref>; <xref ref-type="bibr" rid="bib40">Labbadia and Morimoto, 2013</xref>; <xref ref-type="bibr" rid="bib49">Mochel and Haller, 2011</xref>), hyperactivity might mirror metabolic dysregulation in subgroups of cortical cells. We used mitochondrial respiration as a marker of metabolic functionality and quantified mitochondrial respiration using high-resolution respirometry of cortical tissues. Mitochondrial respiration was unchanged in cortical tissue of Hdh150 mice suggesting that the observed neuronal hyperactivity occurs prior to metabolic changes (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a–c</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>, Mann-Whitney test, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values).</p></sec><sec id="s2-3"><title>Behavior changes in premanifest VFDO Huntington’s disease mice</title><p>Next, we asked whether hyperactivity and increased synchronicity of cortical networks are associated with behavioral changes in the VFDO animals. A visual discrimination task did not show any aberrations in the Hdh150 animals (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a–d</xref>; <xref ref-type="video" rid="fig3video1">Figure 3—video 1</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>, two-way ANOVA, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values). In contrast, in an open-field test premanifest VDFO Hdh150 animals moved significantly more to the center than WT littermates suggesting anxiolytic effects of the VFDO changes (<xref ref-type="fig" rid="fig3">Figure 3a,b</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>, Mann-Whitney test, p=0.03). Distance travelled (as a measure of motility) did not differ between groups (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1e</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>, Mann-Whitney test, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.38744.016</object-id><label>Figure 3.</label><caption><title>Presymptomatic VFDO Hdh150 mice exhibit anxiolytic behavior.</title><p>(<bold>a</bold>) Representative travel pathways of WT (left) and presymptomatic Hdh150 (right) mice analyzed in a 5 min open field test. (<bold>b</bold>) Increased explorative behavior of Hdh150 animals compared to the WT mice. Mann-Whitney test, p&lt;0.05.</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.38744.018</object-id><label>Figure 3—source data 1.</label><caption><title>Numerical values of <xref ref-type="fig" rid="fig3">Figure 3</xref> and associated supplement figures.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38744-fig3-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig3-v3"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.017</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Presymptomatic VFDO Hdh150 mice did not exhibit deficit in visual discrimination test and explorative behavior in novel object recognition test.</title><p>(<bold>a</bold>) Schema of the visual discrimination task set-up. Left, front view of the touch screen panel. Right, top view of the complete test set-up. A monitor is placed at the end of the unit which simultaneously displays the correct and false choice. Both WT and presymptomatic VFDO Hdh150 mice were trained to choose the correct screen and for each correct choice made, a food pellet was released from a reward dispenser placed on the other end of the unit. (<bold>b</bold>) Graph representing time course of the training sessions of WT (dark grey) and presymptomatic Hdh150 (red) mice. Training sessions were carried out for both groups; mice that made at least 70% correct choice for 3 consecutive days were considered for discrimination analysis. After a training period of 7 days, mice were able to perform tasks successfully reaching the 70% criterion (dashed line). Note that no significant difference was observed between WT and Hdh150 mice during the training of visual discrimination task. Repeated measures two-way ANOVA, genotype p=0.6; time p&lt;0.0001; interaction p=0.6. (<bold>c,d</bold>) Time course of visual performance in WT (dark grey) and Hdh150 (red) mice during visual discrimination first of black and white screens (<bold>c</bold>) and then of black and grey screens (<bold>d</bold>). c: Repeated measures two-way ANOVA, genotype p=0.5; time p&lt;0.0001; interaction p=0.03. d: Repeated measures two-way ANOVA, genotype p=0.8; time p&lt;0.01; interaction p=0.9. (<bold>e</bold>) 9-week-old transgenic Hdh150 mice and wildtype littermates received metformin containing (5 mg/ml, met) or pure water over a period of 3 weeks. Groups of WT, Hdh150, WT met and Hdh150 met were analyzed in an open-field test and total distance travelled was measured. Mann-Whitney test, p=0.3.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig3-figsupp1-v3"/></fig><media id="fig3video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-38744-fig3-video1.mp4"><object-id pub-id-type="doi">10.7554/eLife.38744.019</object-id><label>Figure 3—video 1.</label><caption><title>Example of visual discrimination task performed by a trained mouse, real time.</title></caption></media></fig-group><p>Taken together, we have found network hyperactivity in the cortex of VFDO Hdh150 mice combined with anxiolytic behavior.</p></sec><sec id="s2-4"><title>Metformin reduces mutant Htt protein load</title><p>Based on our previous observations that the MID1/PP2A/mTOR protein complex regulates the translation of mHtt protein (<xref ref-type="bibr" rid="bib38">Krauss et al., 2013</xref>) and that treatment with metformin interferes with the MID1 complex (<xref ref-type="bibr" rid="bib36">Kickstein et al., 2010</xref>), we hypothesized that metformin inhibits the MID1/PP2A/mTOR-mediated protein synthesis of mutant mHtt and is therefore a promising candidate molecule to reduce mHtt load and reverse symptoms associated with Huntington’s disease.</p><p>In order to test for an effect of metformin on mHtt protein load and aggregation, HEKT cells stably expressing FLAG-tagged exon 1 of human mHTT carrying 83 CAG repeats were treated with 1 mM or 2.5 mM metformin, or with vehicle for 48 hr. Aggregation was quantified in a filter retardation assay. Metformin reduced the amount of aggregated FLAG-HTT in a concentration-dependent manner (<xref ref-type="fig" rid="fig4">Figure 4a</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, Mann-Whitney test, control vs 2.5 mM metformin p=0.02).</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.38744.020</object-id><label>Figure 4.</label><caption><title>Metformin reduces translation rates of mutant HTT through MID1/PP2A protein complex <italic>in vitro</italic> and decreases both S6 phosphorylation and mutant Htt protein load in Hdh150 animals.</title><p>(<bold>a</bold>) FLAG-HTT detected on a filter retardation assay after treatment with and without 1 mM and 2.5 mM metformin. Quantification on right panel. Mann-Whitney test, control vs. 1 mM metformin p=0.08; control vs. 2.5 mM metformin, p&lt;0.05. (<bold>b</bold>) Stable cell line expressing FLAG-HTT exon1 with 83 CAG repeats transfected with <italic>MID1</italic>-specific siRNAs or control siRNAs in the presence or absence of 2.5 mM metformin. FLAG-HTT detected on a filter retardation assay. Efficiency of the knock-down including Actin as a loading control is shown on a western blot (left panel). Quantification of filter retardation assay on right panel. Mann-Whitney test, control siRNA vs. MID1 siRNA p&lt;0.01; control siRNA vs. MID1 siRNA + metformin p&lt;0.05. (<bold>c</bold>) Protein translation rate of GFP-tagged mutant Htt exon1 (49 CAG repeats) in primary cortical neurons measured in a FRAP-based assay, over a time frame of 4 hr. Lines show the GFP-signal intensity over time in mock-treated (control) and metformin-treated (1 mM and 2.5 mM) cells. Lines represent means, shadowed areas standard deviations. Repeated measures two-way ANOVA, treatment p&lt;0.01, time p&lt;0.0001; interaction p&lt;0.0001. (<bold>d</bold>) Protein translation rate measured in a FRAP-based assay (see c). Lines show the GFP-signal intensity over time in mock-treated (control), metformin-treated (2.5 mM), ocadaic acid (OA)-treated and metformin +OA-treated cells. Shadowed areas show SEM. Repeated measures two-way ANOVA, treatment p&lt;0.01, time p&lt;0.0001, interaction p&lt;0.0001. (<bold>e</bold>) Transgenic Hdh150 mice received metformin-containing water (5 mg/ml, Hdh150 +metformin) or pure water (Hdh150) over a period of 3 weeks. Whole brain lysates were analyzed for the phosphorylation of S6, the expression of total S6, mHtt and wtHtt on western blots. Representative western blots are shown. (<bold>f</bold>) Quantification of pS6 relative to S6. Unpaired t-test, p&lt;0.05. (<bold>g</bold>) mHtt and wt Htt proteins of prefrontal cortex lysates analyzed on western blots after 11 weeks of treatment with metformin (5 mg/ml, Hdh150 +metformin) or pure water (Hdh150). Representative western blots are shown. (<bold>h</bold>) Quantification of mHtt relative to wtHtt. Treatment of 5 mg/ml metformin in the drinking water showed a significant reduction of mHtt protein compared to water control treatment. Unpaired t-test p &lt;&lt;0.05 (<bold>i</bold>) Quantification of mHtt relative to Gapdh. Unpaired t-test, p&lt;0.01. (<bold>j</bold>) Quantification of wtHtt relative to Gapdh. Unpaired t-test, p=0.88.</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.38744.023</object-id><label>Figure 4—source data 1.</label><caption><title>Numerical values of <xref ref-type="fig" rid="fig4">Figure 4</xref> and associated supplement figures.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38744-fig4-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig4-v3"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.021</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Metformin reduces mutant Htt protein translation and does not change drinking behavior of Hdh150CAG animals.</title><p>(<bold>a</bold>) GFP-tagged mutant (49 CAG repeats- Q49) Htt exon1 was expressed in N2A cells and protein translation rate were measured in a FRAP-based assay, in which the GFP signal of transfected cells is removed by photobleaching and the synthesis rate of freshly translated GFP-tagged protein is measured over a time frame of 4 hr. Lines show the GFP-signal intensity over time in mock-treated (control) and metformin (1 mM and 2.5 mM) treated cells. Shadowed areas show standard deviations. Repeated measures two-way ANOVA, treatment p=0.03; time p&lt;0.0001; interaction p&lt;0.0001. (<bold>b</bold>) Male, 9-week-old Hdh150CAG animals were fed with 5 mg/ml metformin in the drinking water (metformin) or with pure water (no metformin) and observed over 21 days. The water consumption was monitored every day. Lines represent means, shadowed areas show ±SEM. Repeated measures two-way ANOVA, treatment p=0.3; time p=0.06; interaction p=1. (<bold>c</bold>) Transgenic Hdh150 mice received metformin-containing water (5 mg/ml, Hdh150 +metformin) or pure water (Hdh150) over a period of 3 weeks. Whole brain lysates were analyzed for the expression of mHtt and wtHtt on western blots. Representative western blots are shown. (<bold>d</bold>) Quantification of mHtt relative to wtHtt. Unpaired t-test, p=0.18.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig4-figsupp1-v3"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.022</object-id><label>Figure 4—figure supplement 2.</label><caption><title>Metformin treatment rescues motility impairment in a <italic>C.elegans</italic> model.</title><p>(<bold>a</bold>) Q40::YFP nematodes were treated with 500 mM of metformin or pure water (control): Images of nematodes with and without metformin treatment for 5 days (left panel): After 5 days of metformin treatment, the number of aggregates was significantly reduced (right panel): Mann-Whitney test, p&lt;0.0001. (<bold>c</bold>) Q40::YFP worms were grown on heat-inactivated bacteria on plates pre-treated with either 5 mM or 10 mM of metformin or with pure water (control). After 5 days of metformin treatment, the number of inclusion bodies was analyzed. Mann-Whitney test, control vs 5 mM metformin, p=0.008; control vs 10 mM metformin, p&lt;0.0001. (<bold>d,e</bold>) RNAi knockdown of the MID1-ortholog arc-1 was performed in Q40::YFP <italic>C. elegans</italic>. After 5 days, the number of inclusion bodies (<bold>d</bold>) and liquid thrashing events (<bold>e</bold>) were analyzed. Mann-Whitney test, p&lt;0.0001.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig4-figsupp2-v3"/></fig></fig-group><p>To test whether the metformin effect on human exon 1 mHTT aggregates is mediated by a blockade of the MID1 protein complex, we depleted MID1 by siRNA-mediated knockdown in the cell line expressing FLAG-HTT exon 1 with 83 CAG repeats, in presence or absence of metformin. While depletion of MID1 reduced mHTT aggregation, no additive effect of metformin treatment on mHTT aggregates was observed, suggesting that MID1 and metformin indeed act through the same pathway (<xref ref-type="fig" rid="fig4">Figure 4b</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, Mann-Whitney test, control siRNA vs MID1 siRNA p=0.009; control siRNA vs MID1 siRNA +metformin p=0.02).</p><p>We had shown previously that the MID1/PP2A/mTOR protein complex regulates the translation efficiency of the human <italic>HTT</italic> mRNA in a repeat-dependent manner (<xref ref-type="bibr" rid="bib38">Krauss et al., 2013</xref>). We therefore looked at a possible influence of metformin on the protein synthesis rate of mHTT exon one protein using a previously described FRAP (Fluorescence recovery after photo bleaching) - based assay that allows monitoring of protein translation rates in living cells (<xref ref-type="bibr" rid="bib38">Krauss et al., 2013</xref>). We detected a clear reduction in the protein synthesis rate of a GFP-Htt fusion protein carrying 49 repeats in the metformin-treated samples in a concentration-dependent manner in primary neurons (<xref ref-type="fig" rid="fig4">Figure 4c</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, RM two-way ANOVA p=0.008). This effect was confirmed in N2A cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, RM two-way ANOVA p=0.03). To further support the contribution of the MID1/PP2A/mTOR protein complex and PP2A activity to this effect, the GFP-Htt transfected cells were subsequently either (i) mock treated, (ii) treated with only metformin, (iii) treated with ocadaic acid (OA), or (iv) co-treated with metformin and OA. OA is an inhibitor of PP2A activity. As expected, OA significantly increased translation rates of the <italic>GFP-</italic>Htt reporter mRNA and metformin did not have a reducing effect on the translation rates in cells co-treated with OA suggesting that indeed the metformin effect is mediated by PP2A activity (<xref ref-type="fig" rid="fig4">Figure 4d</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, RM two-way ANOVA p=0.002).</p><p>To analyze metformin effects on early signs of pathology <italic>in vivo</italic>, VFDO Hdh150 mice were fed with, or without 5 mg/ml metformin in the drinking water. Metformin did not significantly reduce drinking volume (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, RM two-way ANOVA not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values). After 3 weeks of treatment, we looked at phosphorylation patterns of the PP2A/mTOR target S6 and the amount of mHtt protein relative to wild-type Htt in whole brain tissue. The metformin-treated group showed a significant reduction of S6 phosphorylation suggesting an increase in PP2A activity (<xref ref-type="fig" rid="fig4">Figure 4e and f</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, unpaired t-test p=0.05). At the same time, a slight tendency (not significant) of reduced mHtt was detected suggesting that metformin has an influence on mHtt expression (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1c and d</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, unpaired t-test not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values). A significant reduction of mHtt expression, however, became clearly visible after 11 weeks of treatment in cortical tissue (<xref ref-type="fig" rid="fig4">Figure 4g–j</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, unpaired t-test, mHtt/wtHtt p=0.05, mHtt/Gapdh p=0.002, wtHtt/Gapdh p=0.9).</p></sec><sec id="s2-5"><title>Metformin reverses signs of Huntington’s disease pathology</title><p>Our data suggest metformin as a promising molecule to interfere with VFDO Huntington’s disease biochemical and cellular pathological changes. We initially used a <italic>C. elegans</italic> model of polyQ-mediated diseases to test whether metformin effectively ameliorates disease symptoms in an easily controllable model with short lifespan. The <italic>C. elegans</italic> worms carry a transgene encoding YFP-tagged Q40 polypeptide in body wall muscle cells (<xref ref-type="bibr" rid="bib51">Morley et al., 2002</xref>). Adult Q40::YFP nematodes exhibit intracellular aggregates of polyglutamine-containing protein and develop progressive paralysis over time, which is reflected in significantly reduced motility. We counted aggregates in metformin-treated and untreated nematodes. Moreover, we assessed their motility in a liquid thrashing experiment, in which worms are placed in liquid and the frequency of lateral swimming (thrashing) movement is analyzed as a measure of motility. We found that 5 days of metformin treatment reduced the number of intracellular inclusion bodies significantly and rescued motility impairment (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2a and b</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, Mann-Whitney, p&lt;0.0001). Since bacteria can metabolize metformin (<xref ref-type="bibr" rid="bib6">Cabreiro et al., 2013</xref>), we confirmed the results on heat-inactivated OP50 bacteria (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2c</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, Mann-Whitney test, control vs 5 mM metformin p=0.008, control vs 10 mM metformin p&lt;0.0001). siRNA-mediated knock-down of arc-1, the <italic>C.elegans</italic> MID1 homolog, leads to a reduction of inclusion bodies and improved motility similar to the metformin effects (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2d and e</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, Mann-Whitney test, p&lt;0.0001) and confirms that the MID1/PP2A/mTOR protein complex underlies metformin effects.</p><p>We then asked whether metformin could rescue the altered cortical activity <italic>in vivo</italic> in Hdh150 mice. Metformin treatment did not affect the density of OGB-1 stained cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a,b</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, WT: 1413 ± 74 cells/mm<sup>2</sup> (n = 11 mice), Hdh150: 1456 ± 90 cells/mm<sup>2</sup> (n = 10 mice), WT met: 1351 ± 65 cells/mm<sup>2</sup> (n = 9 mice) and Hdh150 met: 1448 ± 60 cells/ mm<sup>2</sup> (n = 6 mice), unpaired t-test, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values). Notably, 3 weeks of metformin treatment in the drinking water completely restored the proportion of active cells (<xref ref-type="fig" rid="fig5">Figure 5b</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, Hdh150: 77.2 ± 3.5% (n = 6 mice), Hdh150 met: 64.4 ± 4.1% (n = 6 mice), Mann-Whitney test p&lt;0.05) and the average frequency of Ca<sup>2+</sup> transients (<xref ref-type="fig" rid="fig5">Figure 5a,c</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, Hdh150: 1.2 ± 0.1 trans/min (n = 6 mice), Hdh150 met: 0.7 ± 0.06% (n = 6 mice), Mann-Whitney test p&lt;0.05). The individual traces of treated Hdh150 animals were indistinguishable from untreated WT animals (<xref ref-type="fig" rid="fig5">Figure 5a</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1c</xref>). Importantly, in these experiments, metformin acts specific on dysregulated network components. Only the AUC of calcium transients was slightly yet significantly affected in WT mice which might be due to an increase of baseline calcium concentration induced by the activation of MID1/PP2A/mTOR signaling pathway (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1c</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). One of the hallmarks of the VFDO Hdh150 mice was the distinct functional subgroup of hyperactive neurons (<xref ref-type="fig" rid="fig1">Figure 1</xref>). We thus assessed the effect of metformin treatment on the relative proportions of low, normal and hyperactive subgroups. Treatment with metformin in Hdh150 mice led to the complete abolishment of the hyperactive subgroup (<xref ref-type="fig" rid="fig5">Figure 5d</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, two-way ANOVA p&lt;0.0001 and <xref ref-type="fig" rid="fig5">Figure 5e</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, Chi-square test not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values) and restored the relative proportion of functional subgroups. The spatial distribution of functional subgroups remained unchanged by metformin treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1f</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, Mann-Whitney test, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values). This complete restoration of dysregulated microcircuit activity was also evident in the cumulative frequency distribution (<xref ref-type="fig" rid="fig5">Figure 5d</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>) and all other network measures found to be aberrant in young Hdh150 animals, such as synchronicity (<xref ref-type="fig" rid="fig5">Figure 5f and g</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1d–e</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>).</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.38744.024</object-id><label>Figure 5.</label><caption><title>Metformin treatment reverses pathological neuronal network activity and behavioral abnormalities in presymptomatic VFDO Hdh150 mice.</title><p>(<bold>a</bold>) Representative traces of spontaneous Ca<sup>2+</sup> transients of 10 neurons recorded <italic>in vivo</italic> in WT and Hdh150 mice after metformin treatment. Vertical scale bar: 40% dF/F. (<bold>b</bold>) Relative proportion of spontaneously active neurons in WT (dark grey), Hdh150 (red), WT metformin-treated (light grey) and Hdh150 metformin-treated (light red) mice. Mann-Whitney test, WT vs. Hdh150, p&lt;0.05; Hdh150 vs. Hdh150 met, p&lt;0.05; Hdh150 vs. WT met, p&lt;0.05. (<bold>c</bold>) Significant reduction in the spontaneous Ca<sup>2+</sup> transient frequency to WT levels in Hdh150 mice after metformin treatment (red vs. light red). Mann-Whitney test, WT vs. Hdh150, p&lt;0.01; Hdh150 vs. Hdh150 met, p&lt;0.01; Hdh150 vs. WT met, p&lt;0.01. (<bold>d</bold>) Cumulative frequency distributions of Ca<sup>2+</sup> transients in WT (dark grey), Hdh150 (red), metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. Top, color-coding of active neurons by frequency. Two-way ANOVA test, Group: p&lt;0.0001; Time: p&lt;0.0001; Interaction: p&lt;0.0001. (<bold>e</bold>) Pie charts showing the relative proportion of low (blue), medium (orange) and hyperactive (red) neurons in layer 2/3 of the visual cortex in WT (top) and Hdh150 (bottom) mice after metformin treatment. Chi-square test, p=0.62, Chi-square = 0.24. (<bold>f</bold>) Comparison of Pearson’s r between a pair of neurons in WT (dark grey), Hdh150 (red), metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. Mann-Whitney test, WT vs. Hdh150, p&lt;0.05, Hdh150 vs. Hdh150 met, p&lt;0.01, Hdh150 vs. WT met, p&lt;0.01. (<bold>g</bold>) Relationship between pairwise Pearson’s r and pairwise distance in metformin-treated WT (light grey) and Hdh150 (light red) mice. Two-way ANOVA test, group p&lt;0.0001; Distance p=0.09; Interaction p&lt;0.001. (<bold>h</bold>) Representative travel pathways of a metformin-treated WT (left) and pre-symptomatic Hdh150 (right) mice analyzed in a 5 min open-field test. (<bold>i</bold>) Decrease in the explorative behavior of metformin-treated Hdh150 animals. Mann-Whitney test, WT vs. Hdh150, p&lt;0.01; Hdh150 vs. Hdh150 met, p&lt;0.001; Hdh150 vs. WT met, p&lt;0.05; WT vs. Hdh150 met, p=0.8.</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.38744.026</object-id><label>Figure 5—source data 1.</label><caption><title>Numerical values of <xref ref-type="fig" rid="fig5">Figure 5</xref> and associated supplement figures.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38744-fig5-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig5-v3"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38744.025</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Metformin treatment does not affect cell density or Ca<sup>2+</sup> transient dynamics</title><p>(<bold>a</bold>) Two-photon images of OGB-1 AM staining collected <italic>in vivo</italic> at different depths (from 150 to 270 µm from pial surface) in the visual cortex of WT and Hdh150 mice after metformin treatment. Scale bar: 70 µm. (<bold>b</bold>) Quantification of the density of stained cells in layer 2/3 of the visual cortex in WT (black), Hdh150 (red, n = 10 animals), metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. No significant difference was found in the cell density across genotypes. Unpaired t-test, p=0.7. (<bold>c</bold>) Area under the curve (AUC) of Ca<sup>2+</sup> transients in WT (black), Hdh150 (red), metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. Unpaired t-test, WT vs. WT met, p&lt;0.05. (<bold>d</bold>) Box-and-whisker plot showing Pearson’s r between different combinations of neuron pairs (LL: low-low, LM: low-medium, LH: low-hyper, MM: medium-medium, MH: medium-hyper, HH: hyper-hyper) in metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. There was no statistical difference between WT and Hdh150 mice after metformin treatment. <sup>#</sup> a statistical difference between a pair vs. LL within the same genotype. Unpaired t-test, WT met: LL vs. LM, p&lt;0.05; LL vs. MM, p&lt;0.0001; Hdh150 met: LL vs. MM, p&lt;0.01. (<bold>e</bold>) Comparison of Pearson’s r between different combinations of neuron pairs in WT (dark grey), Hdh150 (red), metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. * a statistical difference between WT within the same functional subgroup. LM WT vs LM Hdh150 and MM WT vs MM Hdh150 p&lt;0.05. (<bold>f</bold>) Pairwise distance for the different neuronal pairs (SS: silent-silent, SL: silent-low, SM: silent-medium, SH: silent-hyper, LL: low-low, LM: low-medium, LH: low-hyper, MM: medium-medium, MH: medium-hyper, HH: hyper-hyper) in metformin-treated WT (light grey) and metformin-treated Hdh150 (light red) mice. No significant difference between metformin-treated WT and metformin-treated Hdh150 mice could be found. Mann-Whitney test, not significant, see <xref ref-type="table" rid="table1">Table 1</xref> for p-values.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-38744-fig5-figsupp1-v3"/></fig></fig-group><p>Accompanying the network dysfunction, we observed anxiolytic behavior in the VFDO Hdh150 mice (see <xref ref-type="fig" rid="fig3">Figure 3a–b</xref>). Treatment with metformin fully reversed the anxiolytic behavior (<xref ref-type="fig" rid="fig5">Figure 5h and i</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, Mann-Whitney test, WT vs Hdh150 p=0.002, Hdh150 vs Hdh150 met p=0.002, Hdh150 vs WT met p=0.03, WT vs Hdh150 met p=0.8).</p><p>In conclusion, our data suggest that metformin, by interfering with the translation rate of mHtt protein, reduces protein load in cell culture and <italic>in vivo</italic> and reverses early Huntington’s disease-related network dysregulations as well as anxiety-related behavioral aberrations in mice. Furthermore, usage of metformin in adult <italic>C. elegans,</italic> a model of polyQ disease, also significantly influences inclusion bodies formation and motility.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we have identified a dysregulation of spontaneous neuronal activity in the visual cortex in a very early stage of a mouse model of Huntington’s disease that corresponds to a very early stage in the premanifest stage in Huntington’s disease mutation carriers (<xref ref-type="fig" rid="fig1">Figure 1a,b</xref>), which might indeed be a distinct pathological disease stage which is very far from disease onset (VFDO). Correspondingly, the visual cortex is one of the first structures affected in patients (<xref ref-type="bibr" rid="bib41">Labuschagne et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Dogan et al., 2013</xref>). This dysregulation is characterized by an increase in cortical network activity patterns, the emergence of a functional subgroup of hyperactive neurons, and enhanced synchronicity. Overall visual cortex functioning seems to be preserved at this early time point of Huntington’s disease course. Network changes are accompanied by subtle behavior alterations including an anxiolytic phenotype, suggesting that at least part of the brain-wide circuitry exhausted its compensational reserve. Anxiety-related abnormalities including anxiolytic behavior have previously been described in the preclinical phase in several other rodent Huntington’s disease models ((<xref ref-type="bibr" rid="bib53">Nguyen et al., 2006</xref>), reviewed in [<xref ref-type="bibr" rid="bib55">Pouladi et al., 2013</xref>]). So far, changes described here represent the earliest identified abnormalities in cortical pathophysiology and behavior in heterozygous Hdh150 animals, which closely resemble the human disease (<xref ref-type="bibr" rid="bib42">Lin et al., 2001</xref>; <xref ref-type="bibr" rid="bib24">Heng et al., 2007</xref>; <xref ref-type="bibr" rid="bib1">Brooks et al., 2012</xref>; <xref ref-type="bibr" rid="bib67">Tallaksen-Greene et al., 2005</xref>). Furthermore, we show that the type II diabetes drug metformin inhibits the translation of mHtt protein and thereby decreases mHtt protein load <italic>in vitro</italic> and <italic>in vivo</italic>. Promisingly, this leads to a complete restoration of VFDO network activity patterns as well as behavior abnormalities under chronic metformin therapy.</p><p>Our data report primal changes in cortical network function in the VFDO stage of Huntington’s disease. A recognition of the network as a pathophysiological entity has recently been suggested in the context of Alzheimer’s disease (<xref ref-type="bibr" rid="bib2">Busche et al., 2008</xref>; <xref ref-type="bibr" rid="bib29">Iaccarino et al., 2016</xref>). Moreover, focus has shifted away from the mechanisms accompanying neuronal and network degeneration and instead moved toward small and subtle functional changes at very early stages of the disease when irrevocable damage to the network has not yet occurred (<xref ref-type="bibr" rid="bib5">Busche and Konnerth, 2016</xref>). Indeed, hyperactive neurons are associated with both advanced and early stages of Alzheimer’s disease, independent of plaque formation (<xref ref-type="bibr" rid="bib3">Busche et al., 2012</xref>; <xref ref-type="bibr" rid="bib2">Busche et al., 2008</xref>). In addition, evidence points toward hyperactive neurons preventing the cortex-wide propagation of slow oscillations in early Alzheimer’s disease (<xref ref-type="bibr" rid="bib4">Busche et al., 2015</xref>).</p><p>We here describe a similarly distinct hyperactive phenotype in very early stages of Huntington’s disease. We conclude that neuronal hyperactivity may be a principle mechanism that develops early not only in Alzheimer’s disease but also in other neurodegenerative diseases. Thus, the notion of early network dysregulation as a therapeutic target may have broad implications.</p><p>Similar to early stages of Alzheimer’s disease hyperactive neurons in Hdh150 animals emerge in the absence of aggregate formation. Also hyperactive cells do not cluster, and reactive astrocytes or cells with activated caspase-3 as a marker of early apoptosis are not found in these early stages of Huntington’s disease. Furthermore, cortical neurons did not exhibit metabolic dysregulation as measured in a mitochondrial respiration assay. Therefore, we may postulate that the cortex merely responds to early pathophysiological events already commencing in subcortical regions, e.g. the striatum. This is well in line with the current emerging hypotheses of disease progression in Alzheimer’s disease. Young Alzheimer’s disease animals develop hyperactivity in a plaque-independent fashion first in the hippocampus (possibly due to higher vulnerability of the hippocampus in Alzheimer’s disease), followed by a similar hyperactivity pattern in the cortex later in the disease process (<xref ref-type="bibr" rid="bib3">Busche et al., 2012</xref>; <xref ref-type="bibr" rid="bib2">Busche et al., 2008</xref>). Furthermore, in Alzheimer’s disease patients, degeneration of cortical projection targets of the hippocampus is associated with hippocampal hyperactivity indicating a connectivity-based spread of network dysregulations eventually leading to neurodegeneration (<xref ref-type="bibr" rid="bib58">Putcha et al., 2011</xref>). Our data indeed suggest an altered activity in subcortical drivers, since unspecific alteration of excitability in individual neurons is unlikely to lead to an increase in synchronicity, but rather would result in a random increase in firing.</p><p>Our data was collected at very early stages of the disease in the Hdh150 mouse model, which corresponds to the VFDO stage in Huntington’s disease patients. The importance of expression of mutant Htt protein during very early phases for disease development has been demonstrated in the BACHD:CAG-Cre<sup>ERT2</sup> mouse (<xref ref-type="bibr" rid="bib50">Molero et al., 2016</xref>). With the help of tamoxifen treatment expression of mutant Htt was turned off early postnatally. Still the typical symptoms of Huntington’s disease at three and nine months of age were observed in the animals. We conclude that only at the VFDO stages, when cellular and network degeneration have not yet been established, preventive strategies will be most effective; only then can we still rescue small homeostatic shifts, prevent spreading and potentially stabilize network function.</p><p>Phenotype reversal could be demonstrated in a tetracyclin-dependent conditional mouse model for Huntington’s disease. Both neuropathological findings and behavior aberrations were found to disappear when mHtt protein production was stopped through a tet-off regulation mechanism in the adult animal (<xref ref-type="bibr" rid="bib72">Yamamoto et al., 2000</xref>). Additional support for the beneficial effect of suppression of aberrant protein production on the Huntington’s disease phenotype stems from several studies with RNA interference (siRNA), or antisense oligonucleotides showing that gene suppression reducing mHtt protein load by 40% or more, is sufficient to significantly ameliorate the Huntington’s disease phenotype (<xref ref-type="bibr" rid="bib23">HD iPSC Consortium, 2017</xref>; <xref ref-type="bibr" rid="bib22">Harper et al., 2005</xref>; <xref ref-type="bibr" rid="bib32">Keiser et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Stanek et al., 2014</xref>). These studies have demonstrated, that (i) the earlier suppression takes place the more robust and beneficial effects on behavior phenotypes are [reviewed in (<xref ref-type="bibr" rid="bib32">Keiser et al., 2016</xref>)] and (ii) that even transient suppression of Htt protein during early disease stages was sufficient to obtain long-term effects on the disease phenotype lasting for months, far beyond the treatment period (<xref ref-type="bibr" rid="bib43">Lu and Yang, 2012</xref>; <xref ref-type="bibr" rid="bib37">Kordasiewicz et al., 2012</xref>).</p><p>However, developing siRNA and antisense oligonucleotides technologies into therapeutics for clinical use is difficult and a long way to go. Difficulties here include toxicity and modes of delivery: so far oligonucleotides have to be regularly injected into the cerebrospinal fluid, which is a huge effort for patients and physicians. Furthermore, a short N-terminal fragment of the mHtt protein, mHttexp1p, that is produced by incomplete exon one splicing and a short poly-adenylated mRNA in several animal models as well as in Huntington’s disease patients rather than full-length mHtt protein was found to be particularly pathogenic. Its occurrence correlates well with age of onset and severity of the disease. This short mRNA is difficult to target by oligonucleotide strategies (<xref ref-type="bibr" rid="bib52">Neueder et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Sathasivam et al., 2013</xref>). We show here that a well-known, widely used, orally delivered small compound, metformin, suppresses mHtt production by targeting both, full-length and mHttex1p, <italic>in vitro</italic> and <italic>in vivo</italic> and thereby significantly reduces mHtt protein load, which makes it a very promising candidate for chronic early onset Huntington’s disease therapy.</p><p>Metformin is an FDA-approved, inexpensive biguanide that has been used in patients with Type II diabetes for decades and is under discussion for cancer preventive therapy (<xref ref-type="bibr" rid="bib11">Demir et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Micic et al., 2011</xref>). Very recently, metformin has been shown to rescue core phenotypic features in a mouse model for fragile X-syndrome, a neurodevelopmental disorder, by normalizing ERK signalling (<xref ref-type="bibr" rid="bib19">Gantois et al., 2017</xref>).</p><p>Metformin had been brought in as a promising compound in Huntington’s disease previously. It has been found to protect cells from the toxicity of mutant Huntingtin protein in a cell culture model (<xref ref-type="bibr" rid="bib30">Jin et al., 2016</xref>). In a study on R6/2 animals, a very aggressive model for Huntington’s disease, Ma and colleagues had found a significant effect on survival rates and hind clasping in male animals only when given metformin in the drinking water starting from week 5 (<xref ref-type="bibr" rid="bib44">Ma et al., 2007</xref>). In relation to the phenotype in the R6/2 animals that develops severe aberrations from 4 weeks on this is a late time point and would be placed in the motor phase stage when projected to the phenotypic time line given in <xref ref-type="fig" rid="fig1">Figure 1a</xref>. We hypothesize here that preventive treatment at a very early stage is important to substantially and stably influence the disease. This is in agreement with observations in a mouse model for spinocerebellar ataxia I, another neurodegenerative disease based on CAG expansion and studies with antisense oligonucleotides in a Huntington’s disease model. Both studies show that gene suppression has more stable effects on the phenotype when performed early enough (<xref ref-type="bibr" rid="bib37">Kordasiewicz et al., 2012</xref>; <xref ref-type="bibr" rid="bib60">Rubinsztein and Orr, 2016</xref>; <xref ref-type="bibr" rid="bib74">Zu et al., 2004</xref>). In line with that only two phenotypic features had been found to react on late metformin treatment- survival rates and frequency of clasping- in the R6/2 animals. Also and again as expected, effect size on animal survival was quite small (p=0.02). Gender differences in response rate seen in this study can possibly be explained by gender differences in disease development and progression at the motor stage, which had been observed in several mouse models (<xref ref-type="bibr" rid="bib46">Menalled et al., 2009</xref>). When disease progression differs, differences in blood brain barrier permeability can be expected (reviewed in [<xref ref-type="bibr" rid="bib66">Sweeney et al., 2018</xref>]) which then is likely to lead to gender specific variation in bioavailability of metformin in the brain. In contrast to this study we here show that <italic>in vivo</italic> metformin has highly significant effects (p=0.03 to p&lt;0.0001) already on primal changes in the very early, VFDO phases of Huntington’s disease making metformin a promising compound for the development of a therapeutic scheme that is based on early prevention of pathology development. While we focused on male mice in this study, to reduce physiological variability due to hormone fluctuations, at the VFDO stage brain barrier changes are not expected to influence bioavailability of metformin.</p><p>Metformin was suggested to lead, through AMPK activation, to a reduction of mHtt aggregates <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib69">Walter et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">Vázquez-Manrique et al., 2016</xref>). In our previous work, however, we have shown that in cortical neurons metformin does not induce phosphorylation of the AMPK target ACC at all and only when given chronically it induces phosphorylation of AMPK itself in vitro. When giving 5 mg/ml metformin in the drinking water for 16 – 24 days to wildtype animals, while phosphorylation of S6 is significantly reduced, AMPK phosphorylation does not change in whole brain extracts (<xref ref-type="bibr" rid="bib36">Kickstein et al., 2010</xref>). This indicates that AMPK activation is likely to depend on the dose. In WT animals as in preclinical Huntington’s disease animals the blood-brain barrier is intact, which limits bioavailability of metformin in the brain. Metformin concentrations needed to influence mTOR/PP2A activity seem to be significantly lower than those needed to influence AMPK activity. Like in the Kickstein et al. paper, in the present study, we used 5 mg/ml metformin in the drinking water, a concentration at which AMPK activation is not expected, but as we show here in the Hdh150 animals, metformin has a significant effect on the phosphorylation of the mTOR/PP2A target S6.</p><p>The effect of Htt loss on brain function is still under debate. SiRNA studies suggest that postnatal reduction of endogenous Htt protein is well tolerated (summarized in [<xref ref-type="bibr" rid="bib32">Keiser et al., 2016</xref>]). However, conditional knock-out animals with a perinatal loss of around 40% of Htt protein in the forebrain show a neurodegenerative phenotype (<xref ref-type="bibr" rid="bib16">Dragatsis et al., 2000</xref>). Likewise, depletion of Htt protein in the adult brain leads to progressive behavior deficits (<xref ref-type="bibr" rid="bib12">Dietrich et al., 2017</xref>). We demonstrate here that metformin has a very specific effect on the expression of mHtt protein only, leaving wild-type Htt that is produced from the non-mutated allele in dominant Huntington’s disease untouched (<xref ref-type="fig" rid="fig4">Figure 4</xref>). This makes metformin the only compound available at present with a specific effect on only mutant but not wild-type Htt protein.</p><p>In support of an effect of metformin in Huntington’s disease patients an <italic>in silico</italic> comparison of cognitive performance of Huntington’s disease patients treated with metformin was performed. In this study, using the Enroll patient cohort, it was shown that diabetic Huntington’s disease patients in the manifest stage treated with metformin had a better cognitive performance than Huntington’s disease patients not treated with metformin (<xref ref-type="bibr" rid="bib25">Hervás et al., 2017</xref>).</p><p>Our data indicate that metformin treatment reverses all cortical network dysregulations <italic>in vivo</italic> in the premanifest VFDO Hdh150 mice including functional sub-group distribution, frequency and synchronicity. Regaining network stability shows promise for ameliorating the molecular pathophysiology, probably by activating intrinsic repair mechanisms as shown in the context of Alzheimer’s disease (<xref ref-type="bibr" rid="bib29">Iaccarino et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Keskin et al., 2017</xref>). Following this network-centered view, restoration of network functions might also prevent secondary damage to the neuronal microcircuit. We therefore propose a shift in experimental treatment strategies: rather than exploring single pathways for target, we might also consider re-balancing network function in the VFDO stages of the disease.</p><p>Taken together, our data provide evidence for the existence of a pathophysiological entity very far from onset of the manifest disease (VFDO) characterized by early homeostatic changes of network activity and, associated with that, subtle behavior alterations. The data also strongly support the observation that, similar to humans, the disease in mice develops over a long period of time. This provides an early critical window of vulnerability and gives opportunities for early therapeutic interference with disease development. So far, all attempts to develop a causative therapy for Huntington’s disease have been unsuccessful [summarized in (<xref ref-type="bibr" rid="bib9">Crook and Housman, 2011</xref>; <xref ref-type="bibr" rid="bib8">Clabough, 2013</xref>)]. In terms of therapeutic intervention, consideration should be given to a chronic treatment of mutation carriers, which covers the critical windows of vulnerability, as early as in the VFDO stages. Such a strategy avoids delaying intervention until clinical signs of the disease are evident, implying that substantial brain damage has already occurred. Our data suggest that metformin has the potential to reduce mHtt protein load and to substantially influence the early development of pathology and, as seen in a <italic>C. elegans</italic> model, protein aggregation and movement aberrations which are pathognomonic for later disease stages. It is an inexpensive substance, well known in long-term clinical usage and has a defined, relatively benign spectrum of side effects. Prescription to mutation carriers from young adulthood on (or even earlier) is possible and will cover these newly discovered critical windows of opportunity for therapy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) <break/>or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Genetic reagent <break/>(<italic>C.elegans</italic>)</td><td><italic>C.elegans</italic> strain AM141, <break/>genotype rmIs133</td><td>University <break/>of Minnesota</td><td>AM141 (WormBase ID) <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/WB-STRAIN:AM141">WB-STRAIN:AM141</ext-link></td><td/></tr><tr><td>Genetic reagent <break/>(<italic>M. Musculus</italic>)</td><td>Hdh150</td><td>Jackson <break/>Laboratory</td><td>#004595 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:004595">IMSR_JAX:004595</ext-link></td><td>Only males <break/>were used</td></tr><tr><td>Cell line <break/>(<italic>H. sapiens</italic>)</td><td>HEK 293T/17</td><td><xref ref-type="bibr" rid="bib62">Scherzinger et al. (1997)</xref></td><td>CRL-11268 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_1926">CVCL_1926</ext-link></td><td/></tr><tr><td>Cell line <break/>(<italic>M. Musculus</italic>)</td><td>Neuro-2A</td><td>ATCC</td><td>ATCC CCL131 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0470">CVCL_0470</ext-link></td><td/></tr><tr><td>Cell line <break/>(<italic>M. Musculus</italic>)</td><td>primary cortical <break/>neurons</td><td>isolated from <break/>NMRI (Janvier)</td><td/><td/></tr><tr><td>Transfected <break/>construct</td><td>pEGFP-C1- <break/>Httex1</td><td><xref ref-type="bibr" rid="bib38">Krauss et al., 2013</xref></td><td>Self-cloned</td><td/></tr><tr><td>Antibody</td><td>rabbit anti- <break/>activated-caspase-3</td><td>Cell signaling</td><td>9661 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2341188">AB_2341188</ext-link></td><td>1 to 500</td></tr><tr><td>Antibody</td><td>mouse anti-NeuN</td><td>Millipore</td><td>MAB377 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2298772">AB_2298772</ext-link></td><td>1 to 500</td></tr><tr><td>Antibody</td><td>rabbit anti-GFAP</td><td>Dako</td><td>Z0334 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10013382">AB_10013382</ext-link></td><td>1 to 1500</td></tr><tr><td>Antibody</td><td>rabbit anti-Htt</td><td>Abcam</td><td>ab109115 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10863082">AB_10863082</ext-link></td><td>WB: 1:850, IHC: <break/>1:200</td></tr><tr><td>Antibody</td><td>Alexa 546 goat <break/>anti-rabbit</td><td>Invitrogen</td><td>A11035 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_143051">AB_143051</ext-link></td><td>1 to 300</td></tr><tr><td>Antibody</td><td>Alexa 647 goat <break/>anti-mouse</td><td>Invitrogen</td><td>A21235 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_141693">AB_141693</ext-link></td><td>1 to 300</td></tr><tr><td>Antibody</td><td>Cy2 donkey <break/>anti-rabbit</td><td>Jackson Immuno Research</td><td>711-225-152 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2340612">AB_2340612</ext-link></td><td>1 to 300</td></tr><tr><td>Antibody</td><td>Alexa 488 goat <break/>anti-rabbit</td><td>Life technologies</td><td>A11008 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_143165">AB_143165</ext-link></td><td>1 to 200</td></tr><tr><td>Antibody</td><td>anti-FLAG M2-Peroxidase</td><td>Sigma-Aldrich</td><td>A8592 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_439702">AB_439702</ext-link></td><td>1 to 3000</td></tr><tr><td>Antibody</td><td>rabbit anti-actin</td><td>Sigma-Aldrich</td><td>A2066 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_476693">AB_476693</ext-link></td><td>1 to 2000</td></tr><tr><td>Antibody</td><td>rabbit anti-pS6</td><td>Cell signaling</td><td>2215 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2630325">AB_2630325</ext-link></td><td>1 to 2000</td></tr><tr><td>Antibody</td><td>mouse anti-GAPDH</td><td>Abcam</td><td>ab8245 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2107448">AB_2107448</ext-link></td><td>1 to 2000</td></tr><tr><td>Antibody</td><td>HRP-anti-mouse</td><td>Dianova</td><td>115-035-072 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2338507">AB_2338507</ext-link></td><td>1 to 6000</td></tr><tr><td>Antibody</td><td>HRP-anti-rabbit</td><td>Dianova</td><td>305-036-003 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2337936">AB_2337936</ext-link></td><td>1 to 6000</td></tr><tr><td>Antibody</td><td>goat anti-rabbit IgG, <break/>AlexaFluor 488 <break/>conjugate</td><td>Life technologies</td><td>A11008 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_143165">AB_143165</ext-link></td><td>1 to 200</td></tr><tr><td>Sequence- <break/>based reagent</td><td>primers 5’-CCC ATT <break/>CAT TGC CTT GCT <break/>GCT AGG-3’ and 5’-CCT <break/>CTG GAC AGG GAA CAG</td><td>Sigma-Aldrich</td><td>custom</td><td/></tr><tr><td>Sequence- <break/>based reagent</td><td>siRNA AATTGACAGAGGAGTGTGATC</td><td>Qiagen</td><td>custom</td><td/></tr><tr><td>Sequence- <break/>based reagent</td><td>siRNA CACCGCAUCCUAGUAUCACACTT</td><td>Qiagen</td><td>custom</td><td/></tr><tr><td>Sequence-based reagent</td><td>siRNA CAGGAUUACAACUUUUAGGAATT</td><td>Qiagen</td><td>custom</td><td/></tr><tr><td>Sequence-based reagent</td><td>siRNA TTGAGTGAG <break/>CGCTATGACAAA</td><td>Qiagen</td><td>custom</td><td/></tr><tr><td>Sequence-based reagent</td><td>siRNA AAGGTGAT <break/>GAGGCTTCGCAAA</td><td>Qiagen</td><td>custom</td><td/></tr><tr><td>Sequence-based reagent</td><td>siRNA TAGAACGTGATGAGTCATCAT</td><td>Qiagen</td><td>custom</td><td/></tr><tr><td>Sequence-based reagent</td><td>non siRNA AATTCTCCGAACGTGTCACGT</td><td>Qiagen</td><td>custom</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Hoechst33342</td><td>Sigma-Aldrich</td><td>B2261 <break/>CHEBI:51232</td><td>1 to 1000</td></tr><tr><td>Chemical compound, drug</td><td>Fluoromount</td><td>Sigma-Aldrich</td><td>F4680</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Fluoroshield Mounting Medium</td><td>Abcam</td><td>ab104135</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>PBS tabletts</td><td>gibco</td><td>18912–014</td><td/></tr><tr><td>Chemical compound, drug</td><td>Triton-X</td><td>Roth</td><td>6683.1 <break/>CHEBI:9750</td><td>0.3%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Tween20</td><td>Roth</td><td>9127.1</td><td>0.1%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Triton X-100</td><td>Sigma-Aldrich</td><td>T8787 CHEBI:9750</td><td>1 – 0.1%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>natural donkey <break/>serum</td><td>Abcam</td><td>ab7475 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2337258">AB_2337258</ext-link></td><td>4 – 2%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>natural goat <break/>serum</td><td>Abcam</td><td>ab7481 <break/>RRID:2532945</td><td>4 – 2%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>natural sheep <break/>serum</td><td>Abcam</td><td>ab7489 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2335034">AB_2335034</ext-link></td><td>20%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>xylocaine</td><td>AstraZeneca</td><td>PUN080440</td><td>2%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>isoflurane</td><td>AbbVie</td><td>8506 CHEBI:6015</td><td>1–1.55%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>PBS</td><td>Life technologies</td><td>18912–014</td><td>1 M</td></tr><tr><td>Chemical <break/>compound, drug</td><td>paraformaldehyde</td><td>Life technologies</td><td>15710 <break/>CHEBI:31962</td><td>diluted to <break/>4%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Oregon-Green BAPTA1 AM</td><td>Molecular probes</td><td>O6807</td><td>1 mM</td></tr><tr><td>Chemical compound, drug</td><td>EGTA</td><td>Sigma-Aldrich</td><td>E4378 <break/>CHEBI:30740</td><td>0.5 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>MgCl2</td><td>Sigma-Aldrich</td><td valign="bottom">M2670 <break/>CHEBI:86345</td><td>3 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>K-lactobionate</td><td>Sigma-Aldrich</td><td>L2398 <break/>CHEBI:55481</td><td>60 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Taurine</td><td>Sigma-Aldrich</td><td>T0625 <break/>CHEBI:15891</td><td>20 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>KH<sub>2</sub>PO<sub>4</sub></td><td>Sigma-Aldrich</td><td>P5655 <break/>CHEBI:63036</td><td>10 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>HEPES</td><td>Sigma-Aldrich</td><td>H3375 <break/>CHEBI:42334</td><td>20 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Sucrose</td><td>Sigma-Aldrich</td><td>S0389 <break/>CHEBI:17992</td><td>110 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>BSA</td><td>Sigma-Aldrich</td><td>A6003</td><td>1 g/L</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Malate</td><td>Sigma-Aldrich</td><td>M1000 <break/>CHEBI:6650</td><td>2 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Pyruvate</td><td>Sigma-Aldrich</td><td>P2256 <break/>CHEBI: 50144</td><td>10 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Glutamate</td><td>Sigma-Aldrich</td><td>G1626 <break/>CHEBI:64243</td><td>20 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>ADP</td><td>Sigma-Aldrich</td><td>A2754 <break/>CHEBI:16761</td><td>5 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Succinate</td><td>Sigma-Aldrich</td><td>S2378 <break/>CHEBI:63686</td><td>10 mM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>FCCP</td><td>Sigma-Aldrich</td><td>C2920 <break/>CHEBI:75458</td><td>0.2 µM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Rotenone</td><td>Sigma-Aldrich</td><td>R8875 <break/>CHEBI:28201</td><td>0.1 µM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Antimycin A</td><td>Sigma-Aldrich</td><td>A8674 <break/>CHEBI:22584</td><td>2 µM</td></tr><tr><td>Chemical <break/>compound, drug</td><td>MgSO<sub>4</sub></td><td>Sigma-Aldrich</td><td>203726 <break/>CHEBI:32599</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>NaCl</td><td>Sigma-Aldrich</td><td>S3014 <break/>CHEBI:26710</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Na<sub>2</sub>HPO<sub>4</sub></td><td>Sigma-Aldrich</td><td>S3264 <break/>CHEBI:34683</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>oligofectamine</td><td>Thermo-Fisher</td><td>12252–011</td><td>0.2%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>metformin</td><td>MP Biomedicals</td><td>157805 <break/>CHEBI:6802</td><td>5 mg/ml</td></tr><tr><td>Chemical compound, drug</td><td>urea</td><td>Roth</td><td>2317.3 <break/>CHEBI:16199</td><td>48%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>Tris</td><td>Roth</td><td>4855.2 <break/>CHEBI:9754</td><td>15 mM</td></tr><tr><td>Chemical compound, drug</td><td>Glycerin</td><td>Roth</td><td>3783.1 <break/>CHEBI:17754</td><td>8.7%</td></tr><tr><td>Chemical compound, drug</td><td>SDS</td><td>Roth</td><td>2326.1 <break/>CHEBI:8984</td><td>1%</td></tr><tr><td>Chemical compound, drug</td><td>mercaptoehanol</td><td>Roth</td><td>4227.3 <break/>CHEBI:41218</td><td>1%</td></tr><tr><td>Chemical <break/>compound, drug</td><td>protease <break/>inhibitors</td><td>Roche</td><td>04 693 116 001</td><td>1 tablet <break/>per 50 ml</td></tr><tr><td>Chemical compound, drug</td><td>Phosstop</td><td>Roche</td><td>04 906 837 001</td><td>2 tablets <break/>per 10 ml</td></tr><tr><td>Software, <break/>algorithm</td><td>GraphPad <break/>Prism</td><td>GraphPad <break/>Prism</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/"><underline>http://www.graphpad.com/</underline></ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td>Igor Pro <break/>6.22 – 6.37</td><td>Wavemetrics</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_000325">SCR_000325</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.wavemetrics.com/products/igorpro/igorpro.htm"><underline>http://www.wave</underline></ext-link> <break/><ext-link ext-link-type="uri" xlink:href="http://www.wavemetrics.com/products/igorpro/igorpro.htm"><underline>metrics.com/products/igorpro/igorpro.htm</underline></ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td>MATLAB R2011a</td><td>Mathworks</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_001622">SCR_001622</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.mathworks.com"><underline>https://www.mathworks.com</underline></ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td>Code use for <break/>Calcium transient <break/>analysis</td><td>this paper</td><td/><td>the code is enclosed <break/>as a source file</td></tr><tr><td>Software, <break/>algorithm</td><td>LaVision BioTec ImSpector <break/>microscopy <break/>software</td><td>LaVision BioTec</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015249">SCR_015249</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.lavisionbiotec.com/"><underline>https://www.lav</underline></ext-link> <break/><ext-link ext-link-type="uri" xlink:href="https://www.lavisionbiotec.com/"><underline>isionbiotec.com/</underline></ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td>Fiji</td><td>Fiji</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002285">SCR_002285</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://fiji.sc"><underline>http://fiji.sc</underline></ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td>Image J</td><td>Image J - NIH</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/"><underline>https://imagej</underline></ext-link> <break/><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/"><underline>.nih.gov/ij/</underline></ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td>EthoVision XT 8.5</td><td>Noldus</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_000441">SCR_000441</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.noldus.com/EthoVision-XT/New"><underline>https://www.</underline></ext-link> <break/><ext-link ext-link-type="uri" xlink:href="https://www.noldus.com/EthoVision-XT/New"><underline>noldus.com/EthoVision-XT/New</underline></ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td>Image lab</td><td>Biorad</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014210">SCR_014210</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.bio-rad.com/en-us/sku/1709690-image-lab-software"><underline>http://www.bio-rad.com/en-us/sku/1709690-image-lab-software</underline></ext-link></td></tr><tr><td>Software, <break/>algorithm</td><td>Oroboros <break/>DatLab</td><td>Oroboros, <break/>Innsbruck, <break/>Austria</td><td/><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.oroboros.at/index.php?id=datlab">http://www.</ext-link> <break/><ext-link ext-link-type="uri" xlink:href="http://www.oroboros.at/index.php?id=datlab">oroboros.at/index.php?id</ext-link> <break/><ext-link ext-link-type="uri" xlink:href="http://www.oroboros.at/index.php?id=datlab">=datlab</ext-link></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>All experimental procedures were performed in accordance with institutional animal welfare guidelines and were approved by the state government of Rhineland-Palatinate, Germany (G14-1-010 and G14-1-017). WT littermates and heterozygous <italic>Hdh</italic><sup>(CAG)150</sup> mice (Hdh150, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:004595">IMSR_JAX:004595</ext-link>) carrying an extended CAG sequence (∼150) replacing the normal length CAG sequence in mouse <italic>Htt</italic> gene were obtained by crossing Hdh150 heterozygous with WT mice (<xref ref-type="bibr" rid="bib42">Lin et al., 2001</xref>).</p><p>Male mice at 10 – 15 weeks of age were used to examine the change in neuronal network activity prior to disease onset and at 14 – 17 weeks of age to examine the effect of <italic>in vivo</italic> metformin treatment. Male mice at 12 – 16 weeks of age were used for behavior studies. Male mice at 13 weeks of age were used for immunohistochemistry. The mice were kept under specific-pathogen-free conditions on a 12 hr light/12 hr darkness cycle with free access to water and food. Mice were genotyped using the primers 5’-CCC ATT CAT TGC CTT GCT GCT AGG-3’ and 5’-CCT CTG GAC AGG GAA CAG TGT TGG-3’ (Sigma-Aldrich) producing 379- and 829-bp-long fragments for WT and mutant alleles, respectively.</p></sec><sec id="s4-2"><title>Surgery for <italic>in vivo</italic> two-photon Ca<sup>2+</sup> imaging</title><p>Mice were prepared for <italic>in vivo</italic> imaging under isoflurane (1 – 1.5% in pure O<sub>2</sub>, AbbVie). Anesthesia depth was assessed by monitoring pinch withdrawal and respiration rate. Body temperature was kept at 37°C with a heating pad (ATC 200, World precision instruments). Local anesthesia (2% xylocaine, AstraZeneca) was applied to the scalp. A custom-made recording chamber was glued to the skull with cyanoacrylic glue (UHU) followed by dental cement (Paladur, Heraeus). Then, a craniotomy of 1.5 × 1.5 mm was performed using stainless steel drill bits. The position of the primary visual cortex was located according to brain atlas coordinates (Bregma −3 to −4.5 mm, 2 – 3 mm lateral to the midline) (<xref ref-type="bibr" rid="bib54">Paxinos and Franklin, 2001</xref>). After surgery, the mouse was subjected to the two-photon imaging setup.</p></sec><sec id="s4-3"><title>Two-photon Ca<sup>2+</sup> imaging</title><p>The fluorescent Oregon-Green BAPTA1 AM (OGB-1 AM, O6807, Molecular Probes) was bulked-loaded in the visual cortex as described previously (<xref ref-type="bibr" rid="bib64">Stosiek et al., 2003</xref>). Anesthesia level was continuously monitored by keeping the breathing rate at 100 – 110 breaths/min. High-speed two-photon Ca<sup>2+</sup> imaging was performed in layer 2/3 (150 to 350 µm from the pial surface) with an upright LaVision BioTec TrimScope II resonant scanning microscope, equipped with a Ti:sapphire excitation laser (Chameleon Ultra II, Coherent) and a 25x (1.1 N.A., MRD77220, Nikon) or 40x (0.8 N.A., NIRAPO, Nikon) objective. The laser was tuned to 800 nm and fluorescence emission was isolated using a band-pass filter (525/50, Semrock) and detected using a GaAsP photomultiplier tube (PMT; H7422-40, Hamamatsu). The TriM Scope II scan head, equipped with a resonant scanner, imaged time-lapses (512 × 512 pixels,~440 × 440 μm field of view) at a maximum frame rate of 30.4 Hz. Time lapses were recorded for 5 – 8 min on average. Imspector software (LaVision BioTec) was used for microscope control and image acquisition.</p></sec><sec id="s4-4"><title>Determining cell number and analysis of Ca<sup>2+</sup> transients</title><p>First, the number of cells loaded with OGB-1 was manually counted in ImageJ (National Institutes of Health). The area containing all the cells was traced freehand and calculated by the software. Functional data were analyzed using custom-written functions in MATLAB R2011a (Mathworks, Natick, MA) and Igor Pro 6.22 – 6.37 (Wavemetrics, Inc., Lake Oswego, OR). The code is attached as <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>. Regions of interest (ROIs) were hand-drawn by tracing the outlines of OGB1-positive neurons. Fluorescence intensities were quantified by averaging pixels inside each ROI for every image in a sequence. The fluorescence values were normalized by user-defined baseline. Specifically, dF/F was defined as the following:<disp-formula id="equ1"><mml:math id="m1"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow> <mml:mi/><mml:mfrac><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi> <mml:mi/><mml:mi>f</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi> <mml:mi/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi> <mml:mi/><mml:mi>a</mml:mi><mml:mi>n</mml:mi> <mml:mi/><mml:mi>R</mml:mi><mml:mi>O</mml:mi><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi> <mml:mi/><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo>-</mml:mo><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi> <mml:mi/><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mi>*</mml:mi><mml:mn>100</mml:mn></mml:math></disp-formula>where the baseline is defined as a mean fluorescence from a 1–3 s silent period in the same ROI. The peak of a Ca<sup>2+</sup> transient was defined as the first derivative to crossed zero, and the second derivative to be negative, and where the amplitude to be greater than three standard deviations (SD) above the mean. The peak location was corrected manually where necessary. Each dF/F trace, sampled at 15.2 – 30.4 Hz sampling frequency, was preprocessed by binomial Gaussian smoothing (20 – 40 iterations) followed by a high pass filter. The baseline was estimated as the median of activity-free 10 s period preceding each peak. The foot and the tail of Ca<sup>2+</sup> transients were determined as the first data point that fell within 0.5 SD of the baseline before and after the peak, respectively. The area under the curve was trapezoidal and measured between the foot and the tail. A distribution histogram of neurons according to their Ca<sup>2+</sup> transient frequency was used to segregate neurons into three functional subgroups. The definition of hyperactive neurons (&gt;3 trans/min) was determined by the absence of neurons above this limit in WT (0.4 ± 0.3%). The criterion used for low active neurons was set to comprise ~25% of the WT neuronal population (25.8 ± 3.9%).</p><p>The distance between two neurons was calculated by Pythagorean theorem after the x,y coordinate was determined for each ROI.</p><p>The randomization of experimental data comprised two steps: first, each raster plot was reassigned to a randomly selected ROI; then, the location of the individual raster event was shuffled randomly, except no spikes were allowed to occur within 1 s of each other.</p></sec><sec id="s4-5"><title>Immunohistochemistry</title><p>Mice were anesthetized with a mixture of ketamine/xylocaine and perfused transcardially with 4% paraformaldehyde (#15710, Life technologies) in 0.1M phosphate buffer and brains were post-fixed. 50-µm-thick sections were sliced using a HM650 V vibratome (ThermoFisher) and collected in phosphate buffer saline (PBS; Life technologies). Floating sections were incubated for 1 hr with PBS containing 4% natural goat serum (NGS, ab7481, Abcam) or 4% natural donkey serum (NDS, ab7475, Abcam) and 1% Triton X-100 (Sigma-Aldrich) at room temperature (RT, 22˚C). Slices were then incubated for 48 hr at 4°C with primary antibodies against the apoptotic marker-cleaved caspase-3 (1:500; rabbit polyclonal; 9661, Cell signaling), neuronal marker NeuN (1:500; mouse monoclonal; MAB377, Millipore) or astrocytic marker GFAP (1:1500; rabbit polyclonal; Z0334, Dako). Slices were incubated for 2 hr at RT with secondary antibody Alexa 546 goat anti-rabbit (1:300, A11035, Invitrogen), Alexa 647 goat anti-mouse (1:300, A21235, Invitrogen) or Cy2 donkey anti-rabbit (711-225-152, Jackson Immuno Research). Primary and secondary antibodies were diluted in PBS containing 2% NGS or 2% NDS and 0.2% Triton X-100. After staining, brain slices were mounted with Fluoroshield Mounting Medium (ab104135, Abcam).</p><p>For Htt staining, brains were embedded in tissue tek (Sakura) and frozen on dry ice with 100% ethanol. 5 – 10 µm sagittal sections were sliced and subjected to antigen retrieval by being placed in 10 mM sodium citrate buffer at 84°C or 90 – 95°C for 15 – 20 min and rinsed with TBS-Triton-X (0.3%, Roth). Subsequently, sections were blocked with 20% sheep or horse serum in TBS-Triton-X for 1 hr at RT. Primary antibody (Htt: 1:200, rabbit monoclonal, ab109115, Abcam) was diluted in TBS-Triton-X and incubated overnight at 4°C. Secondary antibody (1:200, goat anti-rabbit AlexaFluor 488, A11008, Life technologies) in TBS-Triton-X was incubated for 2 hr at RT. Afterwards, sections were embedded in fluoromount (Sigma-Aldrich) including Hoechst33342 (1:1000, B2261, Sigma-Aldrich). Mounted slices were analyzed with a confocal laser-scanning microscope (Leica SP8).</p></sec><sec id="s4-6"><title>Sample preparation for respirometry experiments</title><p>Experimental animals were sacrificed by cervical dislocation immediately before OXPHOS analysis. Brains were micro-dissected on ice and specimens weighed on an analytical balance (Sartorius, CPA1003S; Germany). The micro-dissected brain regions were directly transferred into ice-cold mitochondrial respiration medium MiR05 (EGTA 0.5 mM, MgCl<sub>2</sub>3 mM, K-lactobionate 60 mM, taurine 20 mM, KH<sub>2</sub>PO<sub>4</sub>10 mM, HEPES 20 mM, sucrose 110 mM, BSA 1 g/L, adjusted to pH 7.1) (<xref ref-type="bibr" rid="bib39">Kuznetsov et al., 2000</xref>). The tissue was then homogenized in a pre-cooled 1.5 ml tube with a motorized pestle in MiR05 medium with 10 strokes. Resulting homogenates containing 10 mg tissue wet weight were suspended in 100 µl of ice-cold MiR05 and later 20 µl (2 mg) from the 100 µl tissue suspension was added to each chamber of the Oxygraph-2k, Oroboros Instrument containing 2 ml of MiR05 for OXPHOS analysis (<xref ref-type="bibr" rid="bib27">Holmström et al., 2012</xref>). All chemicals were purchased from Sigma-Aldrich, Germany. The optimized motorized pestle preparation of brain tissue yields a high degree of permeabilization as evident by the minimal effect of digitonin titrations on OXPHOS capacity. Therefore, digitonin is not necessary for this protocol.</p></sec><sec id="s4-7"><title>High-resolution respirometry in tissue</title><p>Tissue homogenates were transferred into calibrated Oxygraph-2k (O2k, Oroboros Instruments, Innsbruck, Austria) 2 ml chambers. Oxygen polarography was performed at 37 ± 0.001°C (electronic Peltier regulation) in O2k chambers and oxygen concentration (μM) as well as oxygen flux per tissue mass (pmol O<sub>2</sub><bold>·</bold>s<sup>− 1</sup><bold>·</bold>mg<sup>− 1</sup>) were recorded real-time using DatLab software (Oroboros Instruments Innsbruck, Austria). A multisubstrate protocol was used to sequentially explore the various components of mitochondrial respiratory capacity. The homogenate was suspended in MiR05, added to the Oxygraph-2k glass chambers and the O<sub>2</sub>flux was allowed to stabilize. A substrate-uncoupler-inhibitor titration (SUIT) protocol was applied to assess qualitative and quantitative mitochondrial changes in Hdh150 transgenic mice and unaffected controls. After stabilization, LEAK respiration was evaluated by adding the complex I (CI) substrates malate (2 mM), pyruvate (10 mM) and glutamate (20 mM). The maximum oxidative phosphorylation (OXPHOS) capacity with CI substrates was attained by the addition of ADP+Mg<sup>2+</sup> (5 mM) (CI<sub>OXPHOS</sub>). For evaluation of maximum OXPHOS capacity of the convergent input from CI and complex II (CII) at saturating ADP-concentration, the CII substrate succinate (10 mM) was added (CI +CII<sub>OXPHOS</sub>). We then uncoupled respiration to examine the maximal capacity of the electron transport system (ETS or CI +II<sub>ETS</sub>) using the protonophore, carbonylcyanide 4 (trifluoromethoxy) phenylhydrazone (FCCP; successive titrations of 0.2 μM until maximal respiration rates were reached). We then examined consumption in the uncoupled state solely due to the activity of complex II by inhibiting complex I with the addition of rotenone (0.1 μM; ETS CII or CII<sub>ETS</sub>). Finally, electron transport through complex III was inhibited by adding antimycin A (2 μM) to obtain the level of residual oxygen consumption (ROX) due to oxidating side reactions outside of mitochondrial respiration. The O<sub>2</sub> flux obtained in each step of the protocol was normalized by the wet weight of the tissue sample used for the analysis and in addition ROX was subtracted from the fluxes in each run to correct for non-mitochondrial respiration (<xref ref-type="bibr" rid="bib26">Hollis et al., 2015</xref>). All respiration experiments comprise 2 – 3 counterbalanced blocks across days. All substrates and inhibitors used were obtained from Sigma.</p></sec><sec id="s4-8"><title>Visual discrimination task</title><p>WT and presymptomatic VFDO Hdh150 mice (13 – 15 weeks of age) were isolated and food deprived for 24 hr. Subsequently, they were placed into an operant chamber with a touchscreen including two windows and a food dispenser on the opposite wall (Med Associates Inc; St. Albans). In order to keep animals motivated to perform the task, their daily food intake was adjusted to maintain body weight at 75 – 80% of their initial body weight during the course of the experiment. The experiment consisted of three phases:</p><p>1) mice were trained to collect a food pellet from the dispenser twice on day 1, 2) mice were trained to nose poke the touchscreen to obtain food pellet reward. They needed to collect and consume the pellet to proceed to the next trial. One daily session was either 30 min or 70 trials. The touch training was over when mice reached 70 trials on three consecutive days. 3) For the visual discrimination task, the screen presented two stimuli (pair 1: black vs. white or pair 2: black vs. grey), one correct, one false, randomly presented left or right. The mice were trained to nose poke the correct stimulus, whereupon a pellet was released. Again, they needed to collect and consume the pellet to proceed to the next trial. One daily session was either 30 min or 100 trials. The task was successful when the mice reached 70% correct trials on three consecutive days.</p></sec><sec id="s4-9"><title>Open field test</title><p>Mice were not habituated to the set-up. Each mouse was removed from its home cage and put into a holding box next to the testing box. Subsequently, the mouse was put into the testing box facing the rear wall. The mice had time to explore the area for 5 min. Time in the center, which was determined as 10 cm away from each wall of the box, was measured automatically by EthoVision XT 8.5, when the center-point of the mouse moved into it.</p></sec><sec id="s4-10"><title>Cell lines and filter retardation assay</title><p>For all cell lines used in this study the identity has been authenticated and mycoplasma contamination has been tested and excluded.</p><p>HEKT cell lines (ATCC, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_1926">CVCL_1926</ext-link>) stably expressing FLAG-tagged HTT-exon 1 with either 51 or 83 CAG repeats under the control of a Tet-off promotor as well as the filter retardation assay were described previously (<xref ref-type="bibr" rid="bib62">Scherzinger et al., 1997</xref>).</p><p>For the filter retardation assay cells were either transfected with a pool of MID1 specific siRNA oligonucleotides (AATTGACAGAGGAGTGTGATC, CACCGCAUCCUAGUAUCACACTT, CAGGAUUACAACUUUUAGGAATT, TTGAGTGAGCGCTATGACAAA, AAGGTGATGAGGCTTCGCAAA, TAGAACGTGATGAGTCATCAT) or non-silencing control oligonucleotides (AATTCTCCGAACGTGTCACGT) using Oligofectamine (Thermo Fisher Scientific) or treated with metformin at a final concentration of 1 mM and 2.5 mM for 24 hr. Cell lysates were soaked through a filter membrane and aggregates were detected using monoclonal anti-FLAG M2-Peroxidase (HRP) antibodies (Sigma-Aldrich). Signals were quantified using the Fiji Software.</p></sec><sec id="s4-11"><title>FRAP (fluorescence recovery after photobleaching)-based assay</title><p>Neuro-2A (a mouse neuroblastoma cell line, ATCC, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0470">CVCL_0470</ext-link>) cells or murine primary cortical neurons (prepared from NMRI mice E14.5 as described previously [<xref ref-type="bibr" rid="bib36">Kickstein et al., 2010</xref>] were transfected with constructs expressing Htt exon1 with 49CAG repeats fused to GFP (vector pEGFP-C1-HTTex1; an N-terminal GFP tag) the day before analysis. Cells were analyzed in a previously established FRAP-based assay to monitor translation in living cells (<xref ref-type="bibr" rid="bib38">Krauss et al., 2013</xref>) using a Zeiss LSM700 confocal microscope. In brief, in contrast to standard FRAP, the GFP-signal of the entire cell was bleached using a 488 nm argon laser and fluorescence recovery was imaged over a time frame of 4 hr. The fluorescence signal was quantified as the sum of the pixel over the cell area, and the resulting total cell fluorescence was normalized to the post-bleach signal, which was set to 100%. Fluorescence recovery curves represent mean ± SEM of at least 35 cells.</p></sec><sec id="s4-12"><title>Caenorhabditis elegans</title><p>The following <italic>C. elegans</italic> strains was used: strain AM141, genotype rmIs133 [unc-54p::Q40::YFP] (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/WB-STRAIN:AM141">WB-STRAIN:AM141</ext-link>). AM141 worms express YFP that is linked to a polyglutamine stretch of 40 glutamines (Q40) in the muscle cells of the body wall. In the early lifetime of the worms YFP-Q40 is soluble and it aggregates gradually over time. This strain is used as a model for polyglutamine diseases like Huntington´s disease, since the 40Q represents a pathological range of the polyglutamine stretch.</p><p>For the treatment with metformin, NGM plates were seeded with OP50 bacteria and dried overnight. For heat inactivation OP50 bacteria were incubated at 70°C for 30 min. Metformin in a concentration of 5 mM, 10 mM or 500 mM was added the next day and dried again before usage. Worms were then put onto the plates and aggregates and liquid trashing were quantified after 5 days.</p><p>Nematodes were synchronized by hypochloride treatment. At day 5 of adulthood the worms were analyzed. Aggregates were counted under a fluorescence stereo microscope after anesthetizing the worms with 25 mM Levamisol on a coverslip. For each experiment 15 – 20 animals were counted. In addition, liquid thrashing was analyzed in 10 – 15 animals per experiment. Therefore, single worms were transferred into one drop of M9 buffer (3 g KH<sub>2</sub>PO<sub>4</sub>, 6 g Na<sub>2</sub>HPO<sub>4</sub>, 5 g NaCl, 1 ml 1 M MgSO<sub>4</sub>, H<sub>2</sub>O to 1 liter) and the rhythmic bending of the worm around its body axis was counted for 30 s. Each experiment was conducted at least three times.</p></sec><sec id="s4-13"><title>Western blots</title><p>For western blotting mice were sacrificed and brains were grinded and shaked in magic mix (48% urea, 15 mM TRIS-HCl (pH7.5), 8.7% glycerin, 1% SDS, 1% mercaptoethanol, complete protease inhibitors (Roche), Phosstop (Roche)) at 4°C with add-on homogenization (QIAshredder). Afterwards, samples were boiled at 95°C and 30 µg protein lysate (40 µg for Htt blot) was loaded on a 10% SDS PAGE gel, resolved (overnight at 100 V for separation of mHtt from wtHtt) and blotted onto a PVDF membrane (BioRad) using TransBlot Turbo (BioRad). Membranes were then blocked with 1% BSA (pS6) or 5% milk (Actin, Gapdh, Htt) in PBS-Tween20 (Roth) and incubated with primary antibody (Actin: 1:2000, A2066, Sigma Aldrich; pS6: 1:2000, 2215, cell signaling; Gapdh: 1:2000, ab8245, abcam; Htt: 1:850, ab109115, abcam) in blocking buffer overnight. Membranes were then washed three times with PBS-Tween20 and subsequently incubated with secondary antibody (1:6000, for Htt 1:4000, Donkey anti-rabbit or anti-mouse, Jackson Immuno Research) for 1 hr in blocking buffer. Subsequently, membranes were again washed three times with PBS-Tween20. Chemiluminescent detection was done by using Western Lightning Plus-ECL (PerkinElmer). Visualisation was performed on a ChemiDoc MP Imaging System (Biorad). Quantification of resulting bands was performed using Image Lab (version 5.2.1).</p></sec><sec id="s4-14"><title>Metformin treatment in vivo</title><p>Both the Hdh150 and WT mice received chronic metformin (MP Biomedicals, LLC; France) administration (5 mg/ml in the drinking water) freshly prepared every day for 3 weeks starting from an age of 9 – 10 weeks.</p></sec><sec id="s4-15"><title>Statistics</title><p>Statistical significance was tested in GraphPad Prism (GraphPad Software Inc., La Jolla, CA). <xref ref-type="table" rid="table1">Table 1</xref> contains all details concerning statistical tests used (name of the test, p-values, F values and degree of freedom). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 and ****p&lt;0.0001. For all data, we first tested for normal distribution using the one-sample Kolmogorov-Smirnov test. In case that the null hypothesis of a normal distribution could not be rejected (for p&gt;0.05), we employed a parametric test, if H<sub>0</sub> could be rejected (for p&lt;0.05) we used non-parametric tests: Mann-Whitney U test for non-parametric data and t test for parametric data. Pearson’s correlation coefficient was used on raster plots that were temporally binned (328 ms per bin) to compare activity patterns between pairs of neurons. Box-and-whisker plots indicate the median (line) of average values from multiple time-lapses, the 25-75<sup>th</sup> percentiles (box) and the 10-90<sup>th</sup> percentiles (whiskers). Graphs show mean ±s.e.m (standard error of the mean).</p></sec><sec id="s4-16"><title>Data availability</title><p>Values used in figures are available on Dryad Digital repository (doi:10.5061/dryad.g3b5272) and the code used for the analysis of calcium imaging is in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgement</title><p>The authors thank all members of the Methner, Schweiger and Stroh labs for advice and helpful discussions. We thank Zeke Barger and Andrea Kronfeld for help in the analysis of two-photon Ca<sup>2+</sup> imaging data. We also thank Ulrich Schmidt for help in behavior experiments and Cheryl Ernest, Ina Vorberg, Dan Ehninger, Simon Rumpel and Oliver Tuescher for proofreading the manuscript. We acknowledge the Caenorhabditis Genetics Center for the worm strain.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Visualization, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Visualization, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Visualization, Writing—original draft</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Software, Formal analysis, Methodology, Writing—original draft</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con14"><p>Resources, Formal analysis, Supervision, Methodology</p></fn><fn fn-type="con" id="con15"><p>Formal analysis, Supervision, Methodology</p></fn><fn fn-type="con" id="con16"><p>Supervision, Methodology</p></fn><fn fn-type="con" id="con17"><p>Data curation, Supervision</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experimental procedures were performed in accordance with institutional animal welfare guidelines and were approved by the state government of Rhineland-Palatinate, Germany (G14-1-010 and G14-1-017).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.38744.027</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-38744-transrepform-v3.docx"/></supplementary-material><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Values used in figures are available on Dryad Digital repository (doi:10.5061/dryad.g3b5272). The code used for the analysis of calcium imaging is attached as a source file. The numerical values for each figure are enclosed as source data files.</p><p>The following dataset was generated:</p><p><related-object content-type="generated-dataset" id="dataset1" source-id="https://dx.doi.org/10.5061/dryad.g3b5272" source-id-type="uri"><collab collab-type="author">Arnoux I</collab><collab collab-type="author">Willam M</collab><collab collab-type="author">Griesche N</collab><collab collab-type="author">Krummeich J</collab><collab collab-type="author">Watari H</collab><collab collab-type="author">Offermann N</collab><collab collab-type="author">Weber S</collab><collab collab-type="author">Narayan Dey P</collab><collab collab-type="author">Chen C</collab><collab collab-type="author">Monteiro O</collab><collab collab-type="author">Buettner S</collab><collab collab-type="author">Meyer K</collab><collab collab-type="author">Bano D</collab><collab collab-type="author">Radyushkin K</collab><collab collab-type="author">Langston R</collab><collab collab-type="author">Lambert JJ</collab><collab collab-type="author">Wanker E</collab><collab collab-type="author">Methner A</collab><collab collab-type="author">Krauss S</collab><collab collab-type="author">Schweiger S</collab><collab collab-type="author">Stroh A</collab><year>2018</year><source>Data from: Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease</source><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.5061/dryad.g3b5272">https://dx.doi.org/10.5061/dryad.g3b5272</ext-link><comment>Available at Dryad Digital Repository under a CC0 Public Domain Dedication</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname> <given-names>S</given-names></name><name><surname>Higgs</surname> <given-names>G</given-names></name><name><surname>Jones</surname> <given-names>L</given-names></name><name><surname>Dunnett</surname> <given-names>SB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Longitudinal analysis of the behavioural phenotype in Hdh(CAG)150 Huntington's disease knock-in mice</article-title><source>Brain Research Bulletin</source><volume>88</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2010.05.004</pub-id><pub-id pub-id-type="pmid">20457230</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busche</surname> <given-names>MA</given-names></name><name><surname>Eichhoff</surname> <given-names>G</given-names></name><name><surname>Adelsberger</surname> <given-names>H</given-names></name><name><surname>Abramowski</surname> <given-names>D</given-names></name><name><surname>Wiederhold</surname> <given-names>KH</given-names></name><name><surname>Haass</surname> <given-names>C</given-names></name><name><surname>Staufenbiel</surname> <given-names>M</given-names></name><name><surname>Konnerth</surname> <given-names>A</given-names></name><name><surname>Garaschuk</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease</article-title><source>Science</source><volume>321</volume><fpage>1686</fpage><lpage>1689</lpage><pub-id pub-id-type="doi">10.1126/science.1162844</pub-id><pub-id pub-id-type="pmid">18802001</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busche</surname> <given-names>MA</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Henning</surname> <given-names>HA</given-names></name><name><surname>Reichwald</surname> <given-names>J</given-names></name><name><surname>Staufenbiel</surname> <given-names>M</given-names></name><name><surname>Sakmann</surname> <given-names>B</given-names></name><name><surname>Konnerth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease</article-title><source>PNAS</source><volume>109</volume><fpage>8740</fpage><lpage>8745</lpage><pub-id pub-id-type="doi">10.1073/pnas.1206171109</pub-id><pub-id pub-id-type="pmid">22592800</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busche</surname> <given-names>MA</given-names></name><name><surname>Kekuš</surname> <given-names>M</given-names></name><name><surname>Adelsberger</surname> <given-names>H</given-names></name><name><surname>Noda</surname> <given-names>T</given-names></name><name><surname>Förstl</surname> <given-names>H</given-names></name><name><surname>Nelken</surname> <given-names>I</given-names></name><name><surname>Konnerth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rescue of long-range circuit dysfunction in Alzheimer's disease models</article-title><source>Nature Neuroscience</source><volume>18</volume><fpage>1623</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1038/nn.4137</pub-id><pub-id pub-id-type="pmid">26457554</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busche</surname> <given-names>MA</given-names></name><name><surname>Konnerth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Impairments of neural circuit function in Alzheimer's disease</article-title><source>Philosophical Transactions of the Royal Society B: Biological Sciences</source><volume>371</volume><elocation-id>20150429</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2015.0429</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabreiro</surname> <given-names>F</given-names></name><name><surname>Au</surname> <given-names>C</given-names></name><name><surname>Leung</surname> <given-names>KY</given-names></name><name><surname>Vergara-Irigaray</surname> <given-names>N</given-names></name><name><surname>Cochemé</surname> <given-names>HM</given-names></name><name><surname>Noori</surname> <given-names>T</given-names></name><name><surname>Weinkove</surname> <given-names>D</given-names></name><name><surname>Schuster</surname> <given-names>E</given-names></name><name><surname>Greene</surname> <given-names>ND</given-names></name><name><surname>Gems</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism</article-title><source>Cell</source><volume>153</volume><fpage>228</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.02.035</pub-id><pub-id pub-id-type="pmid">23540700</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cepeda</surname> <given-names>C</given-names></name><name><surname>Hurst</surname> <given-names>RS</given-names></name><name><surname>Calvert</surname> <given-names>CR</given-names></name><name><surname>Hernández-Echeagaray</surname> <given-names>E</given-names></name><name><surname>Nguyen</surname> <given-names>OK</given-names></name><name><surname>Jocoy</surname> <given-names>E</given-names></name><name><surname>Christian</surname> <given-names>LJ</given-names></name><name><surname>Ariano</surname> <given-names>MA</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease</article-title><source>The Journal of Neuroscience</source><volume>23</volume><fpage>961</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-03-00961.2003</pub-id><pub-id pub-id-type="pmid">12574425</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clabough</surname> <given-names>EB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Huntington's disease: the past, present, and future search for disease modifiers</article-title><source>The Yale Journal of Biology and Medicine</source><volume>86</volume><fpage>217</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">23766742</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname> <given-names>ZR</given-names></name><name><surname>Housman</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Huntington's disease: can mice lead the way to treatment?</article-title><source>Neuron</source><volume>69</volume><fpage>423</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.12.035</pub-id><pub-id pub-id-type="pmid">21315254</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damiano</surname> <given-names>M</given-names></name><name><surname>Galvan</surname> <given-names>L</given-names></name><name><surname>Déglon</surname> <given-names>N</given-names></name><name><surname>Brouillet</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mitochondria in Huntington's disease</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease</source><volume>1802</volume><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2009.07.012</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demir</surname> <given-names>U</given-names></name><name><surname>Koehler</surname> <given-names>A</given-names></name><name><surname>Schneider</surname> <given-names>R</given-names></name><name><surname>Schweiger</surname> <given-names>S</given-names></name><name><surname>Klocker</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells</article-title><source>BMC Cancer</source><volume>14</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-14-52</pub-id><pub-id pub-id-type="pmid">24484909</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname> <given-names>P</given-names></name><name><surname>Johnson</surname> <given-names>IM</given-names></name><name><surname>Alli</surname> <given-names>S</given-names></name><name><surname>Dragatsis</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1006846</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006846</pub-id><pub-id pub-id-type="pmid">28715425</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiFiglia</surname> <given-names>M</given-names></name><name><surname>Sena-Esteves</surname> <given-names>M</given-names></name><name><surname>Chase</surname> <given-names>K</given-names></name><name><surname>Sapp</surname> <given-names>E</given-names></name><name><surname>Pfister</surname> <given-names>E</given-names></name><name><surname>Sass</surname> <given-names>M</given-names></name><name><surname>Yoder</surname> <given-names>J</given-names></name><name><surname>Reeves</surname> <given-names>P</given-names></name><name><surname>Pandey</surname> <given-names>RK</given-names></name><name><surname>Rajeev</surname> <given-names>KG</given-names></name><name><surname>Manoharan</surname> <given-names>M</given-names></name><name><surname>Sah</surname> <given-names>DW</given-names></name><name><surname>Zamore</surname> <given-names>PD</given-names></name><name><surname>Aronin</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits</article-title><source>PNAS</source><volume>104</volume><fpage>17204</fpage><lpage>17209</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708285104</pub-id><pub-id pub-id-type="pmid">17940007</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname> <given-names>I</given-names></name><name><surname>Eickhoff</surname> <given-names>SB</given-names></name><name><surname>Schulz</surname> <given-names>JB</given-names></name><name><surname>Shah</surname> <given-names>NJ</given-names></name><name><surname>Laird</surname> <given-names>AR</given-names></name><name><surname>Fox</surname> <given-names>PT</given-names></name><name><surname>Reetz</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis</article-title><source>Neurodegenerative Diseases</source><volume>12</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1159/000339528</pub-id><pub-id pub-id-type="pmid">22922585</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dombeck</surname> <given-names>DA</given-names></name><name><surname>Graziano</surname> <given-names>MS</given-names></name><name><surname>Tank</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Functional clustering of neurons in motor cortex determined by cellular resolution imaging in awake behaving mice</article-title><source>Journal of Neuroscience</source><volume>29</volume><fpage>13751</fpage><lpage>13760</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2985-09.2009</pub-id><pub-id pub-id-type="pmid">19889987</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dragatsis</surname> <given-names>I</given-names></name><name><surname>Levine</surname> <given-names>MS</given-names></name><name><surname>Zeitlin</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice</article-title><source>Nature Genetics</source><volume>26</volume><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/81593</pub-id><pub-id pub-id-type="pmid">11062468</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>W</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Metabolism in HD: still a relevant mechanism?</article-title><source>Movement Disorders</source><volume>29</volume><fpage>1366</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1002/mds.25992</pub-id><pub-id pub-id-type="pmid">25124273</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Treatment of Huntington's disease</article-title><source>Neurotherapeutics</source><volume>11</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s13311-013-0244-z</pub-id><pub-id pub-id-type="pmid">24366610</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gantois</surname> <given-names>I</given-names></name><name><surname>Khoutorsky</surname> <given-names>A</given-names></name><name><surname>Popic</surname> <given-names>J</given-names></name><name><surname>Aguilar-Valles</surname> <given-names>A</given-names></name><name><surname>Freemantle</surname> <given-names>E</given-names></name><name><surname>Cao</surname> <given-names>R</given-names></name><name><surname>Sharma</surname> <given-names>V</given-names></name><name><surname>Pooters</surname> <given-names>T</given-names></name><name><surname>Nagpal</surname> <given-names>A</given-names></name><name><surname>Skalecka</surname> <given-names>A</given-names></name><name><surname>Truong</surname> <given-names>VT</given-names></name><name><surname>Wiebe</surname> <given-names>S</given-names></name><name><surname>Groves</surname> <given-names>IA</given-names></name><name><surname>Jafarnejad</surname> <given-names>SM</given-names></name><name><surname>Chapat</surname> <given-names>C</given-names></name><name><surname>McCullagh</surname> <given-names>EA</given-names></name><name><surname>Gamache</surname> <given-names>K</given-names></name><name><surname>Nader</surname> <given-names>K</given-names></name><name><surname>Lacaille</surname> <given-names>JC</given-names></name><name><surname>Gkogkas</surname> <given-names>CG</given-names></name><name><surname>Sonenberg</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metformin ameliorates core deficits in a mouse model of fragile X syndrome</article-title><source>Nature Medicine</source><volume>23</volume><fpage>674</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1038/nm.4335</pub-id><pub-id pub-id-type="pmid">28504725</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grienberger</surname> <given-names>C</given-names></name><name><surname>Konnerth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Imaging calcium in neurons</article-title><source>Neuron</source><volume>73</volume><fpage>862</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.02.011</pub-id><pub-id pub-id-type="pmid">22405199</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griesche</surname> <given-names>N</given-names></name><name><surname>Schilling</surname> <given-names>J</given-names></name><name><surname>Weber</surname> <given-names>S</given-names></name><name><surname>Rohm</surname> <given-names>M</given-names></name><name><surname>Pesch</surname> <given-names>V</given-names></name><name><surname>Matthes</surname> <given-names>F</given-names></name><name><surname>Auburger</surname> <given-names>G</given-names></name><name><surname>Krauss</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulation of mRNA translation by MID1: a common mechanism of expanded CAG repeat RNAs</article-title><source>Frontiers in Cellular Neuroscience</source><volume>10</volume><elocation-id>226</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2016.00226</pub-id><pub-id pub-id-type="pmid">27774050</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname> <given-names>SQ</given-names></name><name><surname>Staber</surname> <given-names>PD</given-names></name><name><surname>He</surname> <given-names>X</given-names></name><name><surname>Eliason</surname> <given-names>SL</given-names></name><name><surname>Martins</surname> <given-names>IH</given-names></name><name><surname>Mao</surname> <given-names>Q</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Kotin</surname> <given-names>RM</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Davidson</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model</article-title><source>PNAS</source><volume>102</volume><fpage>5820</fpage><lpage>5825</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501507102</pub-id><pub-id pub-id-type="pmid">15811941</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>HD iPSC Consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice</article-title><source>Nature Neuroscience</source><volume>20</volume><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1038/nn.4532</pub-id><pub-id pub-id-type="pmid">28319609</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname> <given-names>MY</given-names></name><name><surname>Tallaksen-Greene</surname> <given-names>SJ</given-names></name><name><surname>Detloff</surname> <given-names>PJ</given-names></name><name><surname>Albin</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease</article-title><source>Journal of Neuroscience</source><volume>27</volume><fpage>8989</fpage><lpage>8998</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1830-07.2007</pub-id><pub-id pub-id-type="pmid">17715336</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hervás</surname> <given-names>D</given-names></name><name><surname>Fornés-Ferrer</surname> <given-names>V</given-names></name><name><surname>Gómez-Escribano</surname> <given-names>AP</given-names></name><name><surname>Sequedo</surname> <given-names>MD</given-names></name><name><surname>Peiró</surname> <given-names>C</given-names></name><name><surname>Millán</surname> <given-names>JM</given-names></name><name><surname>Vázquez-Manrique</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metformin intake associates with better cognitive function in patients with Huntington's disease</article-title><source>PLoS One</source><volume>12</volume><elocation-id>e0179283</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0179283</pub-id><pub-id pub-id-type="pmid">28632780</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollis</surname> <given-names>F</given-names></name><name><surname>van der Kooij</surname> <given-names>MA</given-names></name><name><surname>Zanoletti</surname> <given-names>O</given-names></name><name><surname>Lozano</surname> <given-names>L</given-names></name><name><surname>Cantó</surname> <given-names>C</given-names></name><name><surname>Sandi</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mitochondrial function in the brain links anxiety with social subordination</article-title><source>PNAS</source><volume>112</volume><fpage>15486</fpage><lpage>15491</lpage><pub-id pub-id-type="doi">10.1073/pnas.1512653112</pub-id><pub-id pub-id-type="pmid">26621716</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmström</surname> <given-names>MH</given-names></name><name><surname>Iglesias-Gutierrez</surname> <given-names>E</given-names></name><name><surname>Zierath</surname> <given-names>JR</given-names></name><name><surname>Garcia-Roves</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tissue-specific control of mitochondrial respiration in obesity-related insulin resistance and diabetes</article-title><source>American Journal of Physiology-Endocrinology and Metabolism</source><volume>302</volume><fpage>E731</fpage><lpage>E739</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00159.2011</pub-id><pub-id pub-id-type="pmid">22252943</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humbert</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Is Huntington disease a developmental disorder?</article-title><source>EMBO Reports</source><volume>11</volume><elocation-id>899</elocation-id><pub-id pub-id-type="doi">10.1038/embor.2010.182</pub-id><pub-id pub-id-type="pmid">21102640</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iaccarino</surname> <given-names>HF</given-names></name><name><surname>Singer</surname> <given-names>AC</given-names></name><name><surname>Martorell</surname> <given-names>AJ</given-names></name><name><surname>Rudenko</surname> <given-names>A</given-names></name><name><surname>Gao</surname> <given-names>F</given-names></name><name><surname>Gillingham</surname> <given-names>TZ</given-names></name><name><surname>Mathys</surname> <given-names>H</given-names></name><name><surname>Seo</surname> <given-names>J</given-names></name><name><surname>Kritskiy</surname> <given-names>O</given-names></name><name><surname>Abdurrob</surname> <given-names>F</given-names></name><name><surname>Adaikkan</surname> <given-names>C</given-names></name><name><surname>Canter</surname> <given-names>RG</given-names></name><name><surname>Rueda</surname> <given-names>R</given-names></name><name><surname>Brown</surname> <given-names>EN</given-names></name><name><surname>Boyden</surname> <given-names>ES</given-names></name><name><surname>Tsai</surname> <given-names>LH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gamma frequency entrainment attenuates amyloid load and modifies microglia</article-title><source>Nature</source><volume>540</volume><fpage>230</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/nature20587</pub-id><pub-id pub-id-type="pmid">27929004</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name><name><surname>Anders</surname> <given-names>NM</given-names></name><name><surname>Ren</surname> <given-names>T</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Tao</surname> <given-names>M</given-names></name><name><surname>Peng</surname> <given-names>Q</given-names></name><name><surname>Rudek</surname> <given-names>MA</given-names></name><name><surname>Duan</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Metformin protects cells from mutant huntingtin toxicity through activation of AMPK and modulation of mitochondrial dynamics</article-title><source>NeuroMolecular Medicine</source><volume>18</volume><fpage>581</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1007/s12017-016-8412-z</pub-id><pub-id pub-id-type="pmid">27225841</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>YN</given-names></name><name><surname>Johnson</surname> <given-names>GV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease</article-title><source>Journal of Bioenergetics and Biomembranes</source><volume>42</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s10863-010-9286-7</pub-id><pub-id pub-id-type="pmid">20556492</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname> <given-names>MS</given-names></name><name><surname>Kordasiewicz</surname> <given-names>HB</given-names></name><name><surname>McBride</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia</article-title><source>Human Molecular Genetics</source><volume>25</volume><fpage>R53</fpage><lpage>R64</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv442</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname> <given-names>JN</given-names></name><name><surname>Greenberg</surname> <given-names>D</given-names></name><name><surname>Helmchen</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Imaging input and output of neocortical networks in vivo</article-title><source>PNAS</source><volume>102</volume><fpage>14063</fpage><lpage>14068</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506029102</pub-id><pub-id pub-id-type="pmid">16157876</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerschbamer</surname> <given-names>E</given-names></name><name><surname>Biagioli</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Huntington's disease as neurodevelopmental disorder: altered chromatin regulation, coding, and non-coding RNA transcription</article-title><source>Frontiers in Neuroscience</source><volume>9</volume><elocation-id>509</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2015.00509</pub-id><pub-id pub-id-type="pmid">26793052</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keskin</surname> <given-names>AD</given-names></name><name><surname>Kekuš</surname> <given-names>M</given-names></name><name><surname>Adelsberger</surname> <given-names>H</given-names></name><name><surname>Neumann</surname> <given-names>U</given-names></name><name><surname>Shimshek</surname> <given-names>DR</given-names></name><name><surname>Song</surname> <given-names>B</given-names></name><name><surname>Zott</surname> <given-names>B</given-names></name><name><surname>Peng</surname> <given-names>T</given-names></name><name><surname>Förstl</surname> <given-names>H</given-names></name><name><surname>Staufenbiel</surname> <given-names>M</given-names></name><name><surname>Nelken</surname> <given-names>I</given-names></name><name><surname>Sakmann</surname> <given-names>B</given-names></name><name><surname>Konnerth</surname> <given-names>A</given-names></name><name><surname>Busche</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>BACE inhibition-dependent repair of Alzheimer's pathophysiology</article-title><source>PNAS</source><volume>114</volume><fpage>8631</fpage><lpage>8636</lpage><pub-id pub-id-type="doi">10.1073/pnas.1708106114</pub-id><pub-id pub-id-type="pmid">28739891</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kickstein</surname> <given-names>E</given-names></name><name><surname>Krauss</surname> <given-names>S</given-names></name><name><surname>Thornhill</surname> <given-names>P</given-names></name><name><surname>Rutschow</surname> <given-names>D</given-names></name><name><surname>Zeller</surname> <given-names>R</given-names></name><name><surname>Sharkey</surname> <given-names>J</given-names></name><name><surname>Williamson</surname> <given-names>R</given-names></name><name><surname>Fuchs</surname> <given-names>M</given-names></name><name><surname>Köhler</surname> <given-names>A</given-names></name><name><surname>Glossmann</surname> <given-names>H</given-names></name><name><surname>Schneider</surname> <given-names>R</given-names></name><name><surname>Sutherland</surname> <given-names>C</given-names></name><name><surname>Schweiger</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling</article-title><source>PNAS</source><volume>107</volume><fpage>21830</fpage><lpage>21835</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912793107</pub-id><pub-id pub-id-type="pmid">21098287</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kordasiewicz</surname> <given-names>HB</given-names></name><name><surname>Stanek</surname> <given-names>LM</given-names></name><name><surname>Wancewicz</surname> <given-names>EV</given-names></name><name><surname>Mazur</surname> <given-names>C</given-names></name><name><surname>McAlonis</surname> <given-names>MM</given-names></name><name><surname>Pytel</surname> <given-names>KA</given-names></name><name><surname>Artates</surname> <given-names>JW</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>SH</given-names></name><name><surname>Shihabuddin</surname> <given-names>LS</given-names></name><name><surname>Hung</surname> <given-names>G</given-names></name><name><surname>Bennett</surname> <given-names>CF</given-names></name><name><surname>Cleveland</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis</article-title><source>Neuron</source><volume>74</volume><fpage>1031</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.05.009</pub-id><pub-id pub-id-type="pmid">22726834</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauss</surname> <given-names>S</given-names></name><name><surname>Griesche</surname> <given-names>N</given-names></name><name><surname>Jastrzebska</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Rutschow</surname> <given-names>D</given-names></name><name><surname>Achmüller</surname> <given-names>C</given-names></name><name><surname>Dorn</surname> <given-names>S</given-names></name><name><surname>Boesch</surname> <given-names>SM</given-names></name><name><surname>Lalowski</surname> <given-names>M</given-names></name><name><surname>Wanker</surname> <given-names>E</given-names></name><name><surname>Schneider</surname> <given-names>R</given-names></name><name><surname>Schweiger</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>1511</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2514</pub-id><pub-id pub-id-type="pmid">23443539</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsov</surname> <given-names>AV</given-names></name><name><surname>Brandacher</surname> <given-names>G</given-names></name><name><surname>Steurer</surname> <given-names>W</given-names></name><name><surname>Margreiter</surname> <given-names>R</given-names></name><name><surname>Gnaiger</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Isolated rat heart mitochondria and whole rat heart as models for mitochondrial cold ischemia-reperfusion injury</article-title><source>Transplantation Proceedings</source><volume>32</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.1016/S0041-1345(99)00869-6</pub-id><pub-id pub-id-type="pmid">10700961</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labbadia</surname> <given-names>J</given-names></name><name><surname>Morimoto</surname> <given-names>RI</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Huntington's disease: underlying molecular mechanisms and emerging concepts</article-title><source>Trends in Biochemical Sciences</source><volume>38</volume><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2013.05.003</pub-id><pub-id pub-id-type="pmid">23768628</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labuschagne</surname> <given-names>I</given-names></name><name><surname>Cassidy</surname> <given-names>AM</given-names></name><name><surname>Scahill</surname> <given-names>RI</given-names></name><name><surname>Johnson</surname> <given-names>EB</given-names></name><name><surname>Rees</surname> <given-names>E</given-names></name><name><surname>O'Regan</surname> <given-names>A</given-names></name><name><surname>Queller</surname> <given-names>S</given-names></name><name><surname>Frost</surname> <given-names>C</given-names></name><name><surname>Leavitt</surname> <given-names>BR</given-names></name><name><surname>Dürr</surname> <given-names>A</given-names></name><name><surname>Roos</surname> <given-names>R</given-names></name><name><surname>Owen</surname> <given-names>G</given-names></name><name><surname>Borowsky</surname> <given-names>B</given-names></name><name><surname>Tabrizi</surname> <given-names>SJ</given-names></name><name><surname>Stout</surname> <given-names>JC</given-names></name><collab>TRACK-HD Investigators</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Visuospatial processing deficits linked to posterior brain regions in premanifest and early stage Huntington's Disease</article-title><source>Journal of the International Neuropsychological Society</source><volume>22</volume><fpage>595</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1017/S1355617716000321</pub-id><pub-id pub-id-type="pmid">27211109</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>CH</given-names></name><name><surname>Tallaksen-Greene</surname> <given-names>S</given-names></name><name><surname>Chien</surname> <given-names>WM</given-names></name><name><surname>Cearley</surname> <given-names>JA</given-names></name><name><surname>Jackson</surname> <given-names>WS</given-names></name><name><surname>Crouse</surname> <given-names>AB</given-names></name><name><surname>Ren</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>XJ</given-names></name><name><surname>Albin</surname> <given-names>RL</given-names></name><name><surname>Detloff</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Neurological abnormalities in a knock-in mouse model of Huntington's disease</article-title><source>Human Molecular Genetics</source><volume>10</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1093/hmg/10.2.137</pub-id><pub-id pub-id-type="pmid">11152661</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>XH</given-names></name><name><surname>Yang</surname> <given-names>XW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>&quot;Huntingtin holiday&quot;: progress toward an antisense therapy for Huntington's disease</article-title><source>Neuron</source><volume>74</volume><fpage>964</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.06.001</pub-id><pub-id pub-id-type="pmid">22726826</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>TC</given-names></name><name><surname>Buescher</surname> <given-names>JL</given-names></name><name><surname>Oatis</surname> <given-names>B</given-names></name><name><surname>Funk</surname> <given-names>JA</given-names></name><name><surname>Nash</surname> <given-names>AJ</given-names></name><name><surname>Carrier</surname> <given-names>RL</given-names></name><name><surname>Hoyt</surname> <given-names>KR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Metformin therapy in a transgenic mouse model of Huntington's disease</article-title><source>Neuroscience Letters</source><volume>411</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2006.10.039</pub-id><pub-id pub-id-type="pmid">17110029</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehler</surname> <given-names>MF</given-names></name><name><surname>Gokhan</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Mechanisms underlying neural cell death in neurodegenerative diseases: alterations of a developmentally-mediated cellular rheostat</article-title><source>Trends in Neurosciences</source><volume>23</volume><fpage>599</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(00)01705-7</pub-id><pub-id pub-id-type="pmid">11137149</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menalled</surname> <given-names>L</given-names></name><name><surname>El-Khodor</surname> <given-names>BF</given-names></name><name><surname>Patry</surname> <given-names>M</given-names></name><name><surname>Suárez-Fariñas</surname> <given-names>M</given-names></name><name><surname>Orenstein</surname> <given-names>SJ</given-names></name><name><surname>Zahasky</surname> <given-names>B</given-names></name><name><surname>Leahy</surname> <given-names>C</given-names></name><name><surname>Wheeler</surname> <given-names>V</given-names></name><name><surname>Yang</surname> <given-names>XW</given-names></name><name><surname>MacDonald</surname> <given-names>M</given-names></name><name><surname>Morton</surname> <given-names>AJ</given-names></name><name><surname>Bates</surname> <given-names>G</given-names></name><name><surname>Leeds</surname> <given-names>J</given-names></name><name><surname>Park</surname> <given-names>L</given-names></name><name><surname>Howland</surname> <given-names>D</given-names></name><name><surname>Signer</surname> <given-names>E</given-names></name><name><surname>Tobin</surname> <given-names>A</given-names></name><name><surname>Brunner</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models</article-title><source>Neurobiology of Disease</source><volume>35</volume><fpage>319</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.05.007</pub-id><pub-id pub-id-type="pmid">19464370</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micic</surname> <given-names>D</given-names></name><name><surname>Cvijovic</surname> <given-names>G</given-names></name><name><surname>Trajkovic</surname> <given-names>V</given-names></name><name><surname>Duntas</surname> <given-names>LH</given-names></name><name><surname>Polovina</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Metformin: its emerging role in oncology</article-title><source>Hormones</source><volume>10</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.14310/horm.2002.1288</pub-id><pub-id pub-id-type="pmid">21349801</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>JE</given-names></name><name><surname>Ayzenshtat</surname> <given-names>I</given-names></name><name><surname>Carrillo-Reid</surname> <given-names>L</given-names></name><name><surname>Yuste</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Visual stimuli recruit intrinsically generated cortical ensembles</article-title><source>PNAS</source><volume>111</volume><fpage>E4053</fpage><lpage>E4061</lpage><pub-id pub-id-type="doi">10.1073/pnas.1406077111</pub-id><pub-id pub-id-type="pmid">25201983</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mochel</surname> <given-names>F</given-names></name><name><surname>Haller</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Energy deficit in Huntington disease: why it matters</article-title><source>Journal of Clinical Investigation</source><volume>121</volume><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1172/JCI45691</pub-id><pub-id pub-id-type="pmid">21285522</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molero</surname> <given-names>AE</given-names></name><name><surname>Arteaga-Bracho</surname> <given-names>EE</given-names></name><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Gulinello</surname> <given-names>M</given-names></name><name><surname>Winchester</surname> <given-names>ML</given-names></name><name><surname>Pichamoorthy</surname> <given-names>N</given-names></name><name><surname>Gokhan</surname> <given-names>S</given-names></name><name><surname>Khodakhah</surname> <given-names>K</given-names></name><name><surname>Mehler</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease</article-title><source>PNAS</source><volume>113</volume><fpage>5736</fpage><lpage>5741</lpage><pub-id pub-id-type="doi">10.1073/pnas.1603871113</pub-id><pub-id pub-id-type="pmid">27140644</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname> <given-names>JF</given-names></name><name><surname>Brignull</surname> <given-names>HR</given-names></name><name><surname>Weyers</surname> <given-names>JJ</given-names></name><name><surname>Morimoto</surname> <given-names>RI</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans</article-title><source>PNAS</source><volume>99</volume><fpage>10417</fpage><lpage>10422</lpage><pub-id pub-id-type="doi">10.1073/pnas.152161099</pub-id><pub-id pub-id-type="pmid">12122205</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neueder</surname> <given-names>A</given-names></name><name><surname>Landles</surname> <given-names>C</given-names></name><name><surname>Ghosh</surname> <given-names>R</given-names></name><name><surname>Howland</surname> <given-names>D</given-names></name><name><surname>Myers</surname> <given-names>RH</given-names></name><name><surname>Faull</surname> <given-names>RLM</given-names></name><name><surname>Tabrizi</surname> <given-names>SJ</given-names></name><name><surname>Bates</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>1307</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-01510-z</pub-id><pub-id pub-id-type="pmid">28465506</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>HP</given-names></name><name><surname>Kobbe</surname> <given-names>P</given-names></name><name><surname>Rahne</surname> <given-names>H</given-names></name><name><surname>Wörpel</surname> <given-names>T</given-names></name><name><surname>Jäger</surname> <given-names>B</given-names></name><name><surname>Stephan</surname> <given-names>M</given-names></name><name><surname>Pabst</surname> <given-names>R</given-names></name><name><surname>Holzmann</surname> <given-names>C</given-names></name><name><surname>Riess</surname> <given-names>O</given-names></name><name><surname>Korr</surname> <given-names>H</given-names></name><name><surname>Kántor</surname> <given-names>O</given-names></name><name><surname>Petrasch-Parwez</surname> <given-names>E</given-names></name><name><surname>Wetzel</surname> <given-names>R</given-names></name><name><surname>Osmand</surname> <given-names>A</given-names></name><name><surname>von Hörsten</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease</article-title><source>Human Molecular Genetics</source><volume>15</volume><fpage>3177</fpage><lpage>3194</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl394</pub-id><pub-id pub-id-type="pmid">16984963</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Paxinos</surname> <given-names>G</given-names></name></person-group><person-group person-group-type="author"><name><surname>Franklin</surname> <given-names>KBJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><source>The Mouse Brain in Stereotaxic Coordinates</source><edition>2nd ed XXV</edition><publisher-loc>San Diego</publisher-loc><publisher-name>Academic Press</publisher-name></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouladi</surname> <given-names>MA</given-names></name><name><surname>Morton</surname> <given-names>AJ</given-names></name><name><surname>Hayden</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Choosing an animal model for the study of Huntington's disease</article-title><source>Nature Reviews Neuroscience</source><volume>14</volume><fpage>708</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1038/nrn3570</pub-id><pub-id pub-id-type="pmid">24052178</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Predict-HD Investigators of the Huntington Study Group</collab><name><surname>Duff</surname> <given-names>K</given-names></name><name><surname>Paulsen</surname> <given-names>JS</given-names></name><name><surname>Beglinger</surname> <given-names>LJ</given-names></name><name><surname>Langbehn</surname> <given-names>DR</given-names></name><name><surname>Stout</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study</article-title><source>Biological Psychiatry</source><volume>62</volume><fpage>1341</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2006.11.034</pub-id><pub-id pub-id-type="pmid">17481592</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>PREDICT-HD investigators of the Huntington Study Group</collab><name><surname>Harrington</surname> <given-names>DL</given-names></name><name><surname>Rubinov</surname> <given-names>M</given-names></name><name><surname>Durgerian</surname> <given-names>S</given-names></name><name><surname>Mourany</surname> <given-names>L</given-names></name><name><surname>Reece</surname> <given-names>C</given-names></name><name><surname>Koenig</surname> <given-names>K</given-names></name><name><surname>Bullmore</surname> <given-names>E</given-names></name><name><surname>Long</surname> <given-names>JD</given-names></name><name><surname>Paulsen</surname> <given-names>JS</given-names></name><name><surname>Rao</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Network topology and functional connectivity disturbances precede the onset of Huntington's disease</article-title><source>Brain</source><volume>138</volume><fpage>2332</fpage><lpage>2346</lpage><pub-id pub-id-type="doi">10.1093/brain/awv145</pub-id><pub-id pub-id-type="pmid">26059655</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putcha</surname> <given-names>D</given-names></name><name><surname>Brickhouse</surname> <given-names>M</given-names></name><name><surname>O'Keefe</surname> <given-names>K</given-names></name><name><surname>Sullivan</surname> <given-names>C</given-names></name><name><surname>Rentz</surname> <given-names>D</given-names></name><name><surname>Marshall</surname> <given-names>G</given-names></name><name><surname>Dickerson</surname> <given-names>B</given-names></name><name><surname>Sperling</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>17680</fpage><lpage>17688</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4740-11.2011</pub-id><pub-id pub-id-type="pmid">22131428</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname> <given-names>CA</given-names></name><name><surname>Aylward</surname> <given-names>EH</given-names></name><name><surname>Wild</surname> <given-names>EJ</given-names></name><name><surname>Langbehn</surname> <given-names>DR</given-names></name><name><surname>Long</surname> <given-names>JD</given-names></name><name><surname>Warner</surname> <given-names>JH</given-names></name><name><surname>Scahill</surname> <given-names>RI</given-names></name><name><surname>Leavitt</surname> <given-names>BR</given-names></name><name><surname>Stout</surname> <given-names>JC</given-names></name><name><surname>Paulsen</surname> <given-names>JS</given-names></name><name><surname>Reilmann</surname> <given-names>R</given-names></name><name><surname>Unschuld</surname> <given-names>PG</given-names></name><name><surname>Wexler</surname> <given-names>A</given-names></name><name><surname>Margolis</surname> <given-names>RL</given-names></name><name><surname>Tabrizi</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Huntington disease: natural history, biomarkers and prospects for therapeutics</article-title><source>Nature Reviews Neurology</source><volume>10</volume><fpage>204</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.24</pub-id><pub-id pub-id-type="pmid">24614516</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinsztein</surname> <given-names>DC</given-names></name><name><surname>Orr</surname> <given-names>HT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: there may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile</article-title><source>BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology</source><volume>38</volume><fpage>977</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1002/bies.201600048</pub-id><pub-id pub-id-type="pmid">27479863</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathasivam</surname> <given-names>K</given-names></name><name><surname>Neueder</surname> <given-names>A</given-names></name><name><surname>Gipson</surname> <given-names>TA</given-names></name><name><surname>Landles</surname> <given-names>C</given-names></name><name><surname>Benjamin</surname> <given-names>AC</given-names></name><name><surname>Bondulich</surname> <given-names>MK</given-names></name><name><surname>Smith</surname> <given-names>DL</given-names></name><name><surname>Faull</surname> <given-names>RL</given-names></name><name><surname>Roos</surname> <given-names>RA</given-names></name><name><surname>Howland</surname> <given-names>D</given-names></name><name><surname>Detloff</surname> <given-names>PJ</given-names></name><name><surname>Housman</surname> <given-names>DE</given-names></name><name><surname>Bates</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease</article-title><source>PNAS</source><volume>110</volume><fpage>2366</fpage><lpage>2370</lpage><pub-id pub-id-type="doi">10.1073/pnas.1221891110</pub-id><pub-id pub-id-type="pmid">23341618</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherzinger</surname> <given-names>E</given-names></name><name><surname>Lurz</surname> <given-names>R</given-names></name><name><surname>Turmaine</surname> <given-names>M</given-names></name><name><surname>Mangiarini</surname> <given-names>L</given-names></name><name><surname>Hollenbach</surname> <given-names>B</given-names></name><name><surname>Hasenbank</surname> <given-names>R</given-names></name><name><surname>Bates</surname> <given-names>GP</given-names></name><name><surname>Davies</surname> <given-names>SW</given-names></name><name><surname>Lehrach</surname> <given-names>H</given-names></name><name><surname>Wanker</surname> <given-names>EE</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo</article-title><source>Cell</source><volume>90</volume><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80514-0</pub-id><pub-id pub-id-type="pmid">9267034</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanek</surname> <given-names>LM</given-names></name><name><surname>Sardi</surname> <given-names>SP</given-names></name><name><surname>Mastis</surname> <given-names>B</given-names></name><name><surname>Richards</surname> <given-names>AR</given-names></name><name><surname>Treleaven</surname> <given-names>CM</given-names></name><name><surname>Taksir</surname> <given-names>T</given-names></name><name><surname>Misra</surname> <given-names>K</given-names></name><name><surname>Cheng</surname> <given-names>SH</given-names></name><name><surname>Shihabuddin</surname> <given-names>LS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease</article-title><source>Human Gene Therapy</source><volume>25</volume><fpage>461</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1089/hum.2013.200</pub-id><pub-id pub-id-type="pmid">24484067</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stosiek</surname> <given-names>C</given-names></name><name><surname>Garaschuk</surname> <given-names>O</given-names></name><name><surname>Holthoff</surname> <given-names>K</given-names></name><name><surname>Konnerth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>In vivo two-photon calcium imaging of neuronal networks</article-title><source>PNAS</source><volume>100</volume><fpage>7319</fpage><lpage>7324</lpage><pub-id pub-id-type="doi">10.1073/pnas.1232232100</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname> <given-names>JC</given-names></name><name><surname>Paulsen</surname> <given-names>JS</given-names></name><name><surname>Queller</surname> <given-names>S</given-names></name><name><surname>Solomon</surname> <given-names>AC</given-names></name><name><surname>Whitlock</surname> <given-names>KB</given-names></name><name><surname>Campbell</surname> <given-names>JC</given-names></name><name><surname>Carlozzi</surname> <given-names>N</given-names></name><name><surname>Duff</surname> <given-names>K</given-names></name><name><surname>Beglinger</surname> <given-names>LJ</given-names></name><name><surname>Langbehn</surname> <given-names>DR</given-names></name><name><surname>Johnson</surname> <given-names>SA</given-names></name><name><surname>Biglan</surname> <given-names>KM</given-names></name><name><surname>Aylward</surname> <given-names>EH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Neurocognitive signs in prodromal Huntington disease</article-title><source>Neuropsychology</source><volume>25</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1037/a0020937</pub-id><pub-id pub-id-type="pmid">20919768</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname> <given-names>MD</given-names></name><name><surname>Sagare</surname> <given-names>AP</given-names></name><name><surname>Zlokovic</surname> <given-names>BV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders</article-title><source>Nature Reviews Neurology</source><volume>14</volume><fpage>133</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2017.188</pub-id><pub-id pub-id-type="pmid">29377008</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallaksen-Greene</surname> <given-names>SJ</given-names></name><name><surname>Crouse</surname> <given-names>AB</given-names></name><name><surname>Hunter</surname> <given-names>JM</given-names></name><name><surname>Detloff</surname> <given-names>PJ</given-names></name><name><surname>Albin</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice</article-title><source>Neuroscience</source><volume>131</volume><fpage>843</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2004.10.037</pub-id><pub-id pub-id-type="pmid">15749339</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vázquez-Manrique</surname> <given-names>RP</given-names></name><name><surname>Farina</surname> <given-names>F</given-names></name><name><surname>Cambon</surname> <given-names>K</given-names></name><name><surname>Dolores Sequedo</surname> <given-names>M</given-names></name><name><surname>Parker</surname> <given-names>AJ</given-names></name><name><surname>Millán</surname> <given-names>JM</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Déglon</surname> <given-names>N</given-names></name><name><surname>Neri</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease</article-title><source>Human Molecular Genetics</source><volume>25</volume><fpage>1043</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv513</pub-id><pub-id pub-id-type="pmid">26681807</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname> <given-names>C</given-names></name><name><surname>Clemens</surname> <given-names>LE</given-names></name><name><surname>Müller</surname> <given-names>AJ</given-names></name><name><surname>Fallier-Becker</surname> <given-names>P</given-names></name><name><surname>Proikas-Cezanne</surname> <given-names>T</given-names></name><name><surname>Riess</surname> <given-names>O</given-names></name><name><surname>Metzger</surname> <given-names>S</given-names></name><name><surname>Nguyen</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro</article-title><source>Neuropharmacology</source><volume>108</volume><fpage>24</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.04.041</pub-id><pub-id pub-id-type="pmid">27133377</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname> <given-names>H</given-names></name><name><surname>De Micco</surname> <given-names>R</given-names></name><name><surname>Niccolini</surname> <given-names>F</given-names></name><name><surname>Politis</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Molecular imaging markers to track Huntington's Disease Pathology</article-title><source>Frontiers in Neurology</source><volume>8</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2017.00011</pub-id><pub-id pub-id-type="pmid">28194132</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname> <given-names>RC</given-names></name><name><surname>Sambataro</surname> <given-names>F</given-names></name><name><surname>Vasic</surname> <given-names>N</given-names></name><name><surname>Wolf</surname> <given-names>ND</given-names></name><name><surname>Thomann</surname> <given-names>PA</given-names></name><name><surname>Saft</surname> <given-names>C</given-names></name><name><surname>Landwehrmeyer</surname> <given-names>GB</given-names></name><name><surname>Orth</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Default-mode network changes in preclinical Huntington's disease</article-title><source>Experimental Neurology</source><volume>237</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2012.06.014</pub-id><pub-id pub-id-type="pmid">22742947</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>A</given-names></name><name><surname>Lucas</surname> <given-names>JJ</given-names></name><name><surname>Hen</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease</article-title><source>Cell</source><volume>101</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80623-6</pub-id><pub-id pub-id-type="pmid">10778856</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>ZX</given-names></name><name><surname>Li</surname> <given-names>SH</given-names></name><name><surname>Evans</surname> <given-names>J</given-names></name><name><surname>Pillarisetti</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>XJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease</article-title><source>The Journal of Neuroscience</source><volume>23</volume><fpage>2193</fpage><lpage>2202</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-06-02193.2003</pub-id><pub-id pub-id-type="pmid">12657678</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname> <given-names>T</given-names></name><name><surname>Duvick</surname> <given-names>LA</given-names></name><name><surname>Kaytor</surname> <given-names>MD</given-names></name><name><surname>Berlinger</surname> <given-names>MS</given-names></name><name><surname>Zoghbi</surname> <given-names>HY</given-names></name><name><surname>Clark</surname> <given-names>HB</given-names></name><name><surname>Orr</surname> <given-names>HT</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice</article-title><source>Journal of Neuroscience</source><volume>24</volume><fpage>8853</fpage><lpage>8861</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2978-04.2004</pub-id><pub-id pub-id-type="pmid">15470152</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.38744.031</article-id><title-group><article-title>Decision letter</article-title></title-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Joan S Steffan (Reviewer #2).</p><p>The reviewers discussed the reviews with one another and the Reviewing Editor drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>All reviewers found that this work nicely describes development of an assay to measure alterations in neuronal microcircuits in HdhQ150 knock-in mice at the premanifest stage. The authors show that at an early age of 10-15 weeks, the cortical microcircuit of heterozygous HdhQ150 knock-in HD mice shifts towards a more excitable state with increased synchronicity. As the authors had previously shown that the MID1/PP2A/mTOR protein complex regulates translation efficiency of HTT mRNA in a CAG repeat-dependent manner, and that metformin interferes with the MID1 complex, they show that metformin reduces mutant huntingtin (HTT) translation. The authors went on to determine that metformin reverses signs of HD pathology in vivo. First, they used a <italic>C. elegans</italic> model expressing YFP-tagged Q40 polypeptide in body wall muscle cells and determined that metformin reduced the number of intracellular inclusion bodies and rescued motility impairment, similar to knockdown of Arc-1, the <italic>C. elegans</italic> homolog of MID1. Second, they found that metformin treatment in the drinking water of VFDO HdhQ150 mice completely restored the alterations in cortical microcircuit activity back to wt levels.</p><p>Recent work by the laboratory of Gillian Bates (PNAS 110:266, 2013 and Sci Rep 7, 1307, 2017) has demonstrated that there is incomplete transcription of the mutant HTT gene in knock-in mice and in HD patients, that results in expression of mutant HTT exon 1 protein (mHTTex1p), known to cause Huntington's disease-like pathogenesis in transgenic mice and flies. mHTTex1p has been shown to be cleared by autophagy, a lysosomal process of protein degradation known to decline with age. Full-length HTT itself is an autophagic scaffold, and its levels decline with age in both wt and mutant HD knock-in mice. The ideal therapeutic for HD may be to reduce translation of mHTTex1p in patients in parallel with early presymptomatic activation of autophagy to clear mHTTex1p while lysosomal function is intact, without reducing levels of wt full-length HTT which may be protective. The authors of this manuscript demonstrate that mHTTex1p translation is reduced with metformin treatment, and that in HdhQ150 heterozygotes, only mutant full-length HTT is reduced, but that wt full-length HTT levels are not impacted, although the promising western shown in 4f needs to be redone in triplicate with loading controls added. The authors state that the effect of metformin at the dose they use does not activate AMPK, known to activate autophagy; activation of AMPK-induced autophagy has been found to improve HD pathology in cell culture (Walter 2016). Reduced mTor activity, shown here with metformin treatment of HdhQ150s, is a well-known activator of autophagy. Metformin has also previously been shown by others to activate autophagy, to slow HD pathology in male R6/2 HD transgenic mice, and to improve cognitive function in diabetic HD patients. As the authors point out, metformin is inexpensive and well known in long-term clinical usage with only benign side effects. Metformin might be a wonderful treatment for HD to be tested in gene-positive premanifest patients, as it may reduce levels of toxic mHTTex1p through reduced translation as well autophagy activation, while not affecting wt full-length HTT levels or function. This work is very promising but needs revision on several points.</p><p>Essential revisions:</p><p>1) Female mice were excluded from this study without rationale. In the Discussion, the authors state that Ma et al. reported that only male R6/2 mice benefitted from metformin treatment. These sex-specific differences should be investigated more thoroughly. If this treatment is expected to only be beneficial for males, this needs to be clearly addressed in the text.</p><p>2) Experiments on the behavioral deficits in the mice are not well done. If these mice have a memory consolidation deficit, they should not learn the visual discrimination task. The authors are putting forth that these mice have perfect consolidation in visual training and none in object recognition, a late onset deficit. It is far more likely that these mice have anxiety, a known early onset phenotype in patients and animals, and their neophobia confounds object learning assessment. The test was also performed using objects that the mice could climb on. This is a confound and data from these types of objects is skewed. All in all, this data should be removed and cognitive effects of metformin not addressed in this paper.</p><p>3) The finding that metformin induces mHTT lowering is not convincing. A filter retardation assay demonstrates reduced aggregation, but decreased aggregation does not equal decreased mHTT. The Western image in Figure 4E is unquantifiable. If this is representative, the quantification is not valid. Additionally, instead of a loading control, mHTT is normalized to wt HTT, which pre-supposes perfect specificity for mHTT. Finally, it is suggested that authors eliminate 4E and focus on improving data in Figure 4F by including multiple replicates and a loading control at the later time point. Finally, if metformin does reduce mHTT, this study reports previously unexplored deficits that, like many others, are ameliorated by HTT lowering rather than a basis for a paradigm shift, in which rebalancing network function represents a novel therapeutic strategy for HD. This latter point needs to be presented in their Discussion.</p><p>4) The authors need to expand their review of the background literature in HD to include more on HTT loss in vivo. Molero et al., showing that expression of full-length mHTT only during pre-natal development is sufficient to induce HD-like deficits in adult mice, is cited as rationale for the importance of very early intervention. However, Ai Yamamoto's seminal work demonstrating that adult inactivation of mHTTex1p expression in symptomatic mice leads to a reversal of behavior deficits and neuropathology (Yamamoto et al., 2000), and Gill Bates's recent data demonstrating that mHTTex1p is expressed due to incomplete transcription of the mutant HTT gene in patients, suggest that reduced translation of mHTTex1p in patients may be helpful to slow disease onset. Furthermore, based on cited studies, the authors conclude that postnatal HTT loss does not cause adverse effects, but do not include papers demonstrating that perinatal or adult inactivation of HTT results in a progressive neurodegenerative phenotype and that older animals are more susceptible to this effect (Dragatsis et al., 2000, Dietrich et al., 2017).</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.38744.032</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Female mice were excluded from this study without rationale. In the Discussion, the authors state that Ma et al. reported that only male R6/2 mice benefitted from metformin treatment. These sex-specific differences should be investigated more thoroughly. If this treatment is expected to only be beneficial for males, this needs to be clearly addressed in the text.</p></disp-quote><p>While we conducted an a priori power analysis to determine the sample size based on previous studies on network dysfunction in early-stage Alzheimer’s disease, this is the very first study on cortical microcircuit activity in early stage Huntington’s disease models in vivo. Consequently, the effect size was unknown and could only be approximated. To increase the chances of detecting the hypothesized effect, we chose male mice, thereby minimizing the influence of hormonal fluctuations on network activity. This approach is in line with a recent study in the field of Alzheimer’s disease (Iaccarino et al., 2016), using males only. However, a related paper from another group used female mice, and found a similar network dysregulation in Alzheimer’s disease (Keskin et al., 2017). And the first study on this topic did not even specify the gender used (Busche et al., 2008). Consequently, while we very much agree with the reviewers on the importance of investigating gender specificity, we have no reason to assume, that the phenomenon of network dysregulation itself is limited to male mice only.</p><p>In terms of the gender-specific effects of Metformin treatment, we are aware of the Ma et al. study showing benefits of metformin in male mice only. However, Ma and colleagues have used the R6/2 mouse for their analysis and have started the treatment at 5 weeks of age, which is already late in disease progression (motor phase). The R6/2 mouse is an aggressive model and starts developing motor aberrations already in week 4 (the Hdh mouse model we employed shows first motor aberrations in week 100). We hypothesized that very early treatment in the very far from disease onset phase rather than in later phases is necessary to gain stable effects on the disease phenotype. This is supported by gene suppression studies in animal models of SCA1 (spinocerebellar ataxia I) and Huntington’s disease (summarized in Rubinsztein and Orr, Bioessays 2016) showing that only early intervention leads to stable effects in the animals. The effect sizes are highly significant and include all phenotypic features investigated. Consequently, while we fully acknowledge that there may be additional physiological variability, currently, also in terms of treatment, we do not expect that the treatment will be effective in males only. We very much agree that there needs to be a follow-up study, investigating best dosages and time of metformin treatment, which critically needs to include the investigation of gender specificity. We modified the manuscript accordingly, to make it clear, why our study was conducted in males and included a paragraph on gender specificity in the Materials and methods as well as in the Discussion section.</p><p>“We focused our analysis on male mice, thereby minimizing the influence of hormonal fluctuations on network activity. This approach is in line with a recent study in the field of Alzheimer disease (Iaccarino et al., 2016), using males only.”</p><p>“In a study on R6/2 animals, a very aggressive model for Huntington’s disease, Ma and colleagues had found a significant effect on survival rates and hind clasping in male animals only when given metformin in the drinking water starting from week 5 (Ma et al., 2007). […] While we focused on male mice in this study, to reduce physiological variability due to hormone fluctuations, at the VFDO stage brain barrier changes are not expected to influence bioavailability of metformin.”</p><disp-quote content-type="editor-comment"><p>2) Experiments on the behavioral deficits in the mice are not well done. If these mice have a memory consolidation deficit, they should not learn the visual discrimination task. The authors are putting forth that these mice have perfect consolidation in visual training and none in object recognition, a late onset deficit. It is far more likely that these mice have anxiety, a known early onset phenotype in patients and animals, and their neophobia confounds object learning assessment. The test was also performed using objects that the mice could climb on. This is a confound and data from these types of objects is skewed. All in all, this data should be removed and cognitive effects of metformin not addressed in this paper.</p></disp-quote><p>We have followed the advice of the reviewers and have omitted the data from the manuscript.</p><disp-quote content-type="editor-comment"><p>3) The finding that metformin induces mHTT lowering is not convincing. A filter retardation assay demonstrates reduced aggregation, but decreased aggregation does not equal decreased mHTT. The Western image in Figure 4E is unquantifiable. If this is representative, the quantification is not valid. Additionally, instead of a loading control, mHTT is normalized to wt HTT, which pre-supposes perfect specificity for mHTT. Finally, it is suggested that authors eliminate 4E and focus on improving data in Figure 4F by including multiple replicates and a loading control at the later time point. Finally, if metformin does reduce mHTT, this study reports previously unexplored deficits that, like many others, are ameliorated by HTT lowering rather than a basis for a paradigm shift, in which rebalancing network function represents a novel therapeutic strategy for HD. This latter point needs to be presented in their Discussion.</p></disp-quote><p>We thank the reviewers for their valuable comment.</p><p>We exchanged the western blot shown in Figure 4G, and in Figure 4—figure supplement 1. As suggested by the reviewers, we included Gapdh as loading control. Three analyses of protein level were performed: (i) mHtt/wtHtt (Figure 4H), (ii) mHtt/Gapdh (Figure 4I) and (iii) wtHTT/Gapdh (Figure 4J). Data in Figure 4H-J are from three biological replicates.</p><p>We found that the level of mHtt significantly decreases in Hdh150 met mice when normalized to Gapdh while the level of wtHtt is unchanged by metformin treatment. This indicates that metformin reduces mHtt protein load.</p><p>In addition, our findings of an early network activity shift suggests that, rather than exploring single pathomechanistical pathways for target-identification, we might also consider re-balancing the network as a promising route for future therapy development.</p><p>We have substantially changed the wording as follows: “Our data indicate that metformin treatment reverses all cortical network dysregulations in vivo in the premanifest VFDO Hdh150 mice including functional sub-group distribution, frequency and synchronicity. […] We therefore propose a shift in experimental treatment strategies: rather than exploring single pathways for target-identification we might also consider re-balancing network function in the VFDO stages of the disease.”</p><disp-quote content-type="editor-comment"><p>4) The authors need to expand their review of the background literature in HD to include more on HTT loss in vivo. Molero et al., showing that expression of full-length mHTT only during pre-natal development is sufficient to induce HD-like deficits in adult mice, is cited as rationale for the importance of very early intervention. However, Ai Yamamoto's seminal work demonstrating that adult inactivation of mHTTex1p expression in symptomatic mice leads to a reversal of behavior deficits and neuropathology (Yamamoto et al., 2000), and Gill Bates's recent data demonstrating that mHTTex1p is expressed due to incomplete transcription of the mutant HTT gene in patients, suggest that reduced translation of mHTTex1p in patients may be helpful to slow disease onset. Furthermore, based on cited studies, the authors conclude that postnatal HTT loss does not cause adverse effects, but do not include papers demonstrating that perinatal or adult inactivation of HTT results in a progressive neurodegenerative phenotype and that older animals are more susceptible to this effect (Dragatsis et al., 2000, Dietrich et al., 2017).</p></disp-quote><p>This paragraph includes numerous very good suggestions that helped us to substantially strengthen the manuscript. We have included all of them and thank the reviewers for their suggestions:</p><p>We have included Yamamoto’s work in the Discussion:</p><p>“Phenotype reversal could be demonstrated in a tetracyclin dependent conditional mouse model for Huntington’s disease. Both, neuropathological findings and behavior aberrations were found to disappear when mHtt protein production was stopped through a tet-off regulation mechanism in the adult animal (Yamamoto, Lucas, and Hen 2000).”</p><p>We have included Gill Bates’ work in the Discussion:</p><p>“Furthermore, a short N-terminal fragment of the mHtt protein, mHttexp1p, that is produced by incomplete exon 1 splicing and a short poly-adenylated mRNA in several animal models as well as in Huntington’s disease patients rather than full-length mHtt protein was found to be particularly pathogenic. […] This short mRNA is difficult to target by oligonucleotide strategies (Neueder et al. 2017, Sathasivam et al. 2013)”</p><p>We have strengthened the importance of the observation that metformin targets specifically the mutant Htt by discussing the work of Dragatsis et al. and Dietrich et al.: Discussion section:</p><p>“The effect of Htt loss on brain function is still under debate. SiRNA studies suggest that postnatal reduction of endogenous Htt protein is well tolerated (summarized in (Keiser, Kordasiewicz, and McBride 2016). […] Likewise, depletion of Htt protein in the adult brain leads to progressive behavior deficits (Dietrich et al., 2017)”</p></body></sub-article></article>